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The proteasome plays a major role in non-lysosomal protein degradation pathways and
inhibition of proteasomes became a valid therapeutic strategy for anti-cancer therapy in
the recent years. Current e orts focus on the identification and development of second
generation inhibitors with enhanced pharmacological properties. For this, improved struc-
tural knowledge and an advanced biochemical characterization of proteasome inhibition
is necessary.
In this work, I present a reproducible and robust pipeline that enables the purification,
crystallization, crystal handling and structure determination of the native 20S proteasome
and 20S-inhibitor complexes. Crystal structures including four previously uncharacterized
inhibitor complexes with clinically relevant inhibitors were elucidated at resolutions be-
tween 1.8 and 2.1 Å. The improved resolutions allow to define the inhibition chemistry
at atomic resolution. This led to revised descriptions of binding modes for epoxyketone
and ketoaldehyde inhibitors, a redefinition of the proteasome active site, and a concept
for future drug design.
Single particle electron cryomicroscopy (cryo-EM) was the method of choice when study-
ing the influence of 20S core particle inhibition on the dynamic 26S holoenzyme. We
determined structures of the 26S proteasome with and without inhibitor and report for
the first time structural changes of 26S proteasomes upon inhibition. Drug binding limits
the conformational space of the 19S regulatory particle and we identified an energy bar-
rier that stabilizes the proteasome in a non-productive state. Here, we describe that core
particle inhibition triggers a structural long-range allosteric regulation of the human 26S
proteasome.
This thesis o ers insights into the exact catalytic mechanism of peptide cleavage and
proteasome inhibition in the human 20S proteasome and a detailed description of the
proteolytic site. In addition, the structural impact of 20S inhibition on the human 26S
proteasome was studied for the first time and the findings allow for a new way to screen
and develop future allosteric proteasome inhibitors. A reproducible workflow to struc-
turally study inhibitor-proteasome complexes by advanced protein complex purification
combined with X-ray crystallography or single particle cryo-EM is presented.
Keywords: protein complex purification, X-ray crystallography, electron cryomicroscopy,






Protein degradation is a major part of protein homeostasis in the cell. The concept of
protein degradation is at the center of understanding the underlying causes of the ever-
growing list of diseases associated with protein misfolding1 as well as aggregation-related
degenerative disorders2. Proteins in the cell have half-lives that range from a few minutes
to several days and the level of all proteins must be evaluated continuously to uphold
the required balance. The cell’s ability to adapt to changing conditions or to progress
through its general life cycle, ultimately requires a dynamic composition of its proteome.
To maintain normal cell function new proteins are synthesized and old or unused proteins
are degraded3.
In the 1970s, an intracellular, non-lysosomal protein degradation pathway was discov-
ered and today it is known that protein degradation in eukaryotes is almost entirely
undertaken by a complex molecular machine, the proteasome4. The proteasome forms
the center of the ubiquitin-proteasome system (UPS), with critical functions in cell cy-
cle control, protein quality control, programmed cell death by apoptosis, inflammation,
transcription and many more biological processes3. The extent of the UPS is facilitated
by a broad range of ubiquitin ligase enzymes and specific factors. The proteasome is the
only ATP-dependent protease found in eukaryotes and the only one that is ubiquitin de-
pendent5. Structurally, the proteasome is a hybrid of a proteolytic and ATP-dependent
regulatory machinery composed of a 20S core particle and 19S regulatory particle, re-
spectively6.
1.1.1 The Ubiquitin-Proteasome Pathway Mechanism
Degradation of proteins by the UPS is energy dependent and includes two discrete and
successive parts: (1) substrate recognition, whereby the substrate specificity is ensured
by polyubiquitination of substrates by specific enzymes and (2) substrate unfolding to
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make the polypeptide backbone fully accessible for proteolytic cleavage7.
Proteins destined for degradation are modified with polymers of the highly conserved
protein, ubiquitin. The covalent attachment of ubiquitin to the substrate is carried out
by a series of enzymes (Figure 1.1):
Ubiquitin is first activated upon ATP turnover by an E1 ubiquitin activating enzyme,
forming a high energy thiol ester with the carboxyl group at the C-terminus, thereby ac-
tivating the C-terminus of ubiquitin for nucleophilic attack. Subsequently, the activated
ubiquitin molecule is transfered to the active site cysteine of a second enzyme, the E2
ubiquitin conjugating enzyme. The ubiquitin ligase E3 recognizes its substrate, transfers
the activated ubiquitin from the E2 enzyme to the substrate and catalyzes the formation
of an isopeptide bond between a lysine residue of the substrate and the C-terminus of
the ubiquitin. To form polyubiquitin chains, additional ubiquitin molecules are ligated
to Lys48 of the ubiquitin that is already conjugated to the protein substrate8. Generally,
a chain of four or more ubiquitin molecules is necessary to create a targeting signal for
degradation by the proteasome and this three-step mechanism initiates all known ubiq-
uitination reactions, independent of the biological fate9.
In human, numerous enzymes are involved in the UPS: two E1 enzymes, approximately
30 E2 conjugating enzymes and more than 500 E3 ubiquitin ligases, whereby the sub-
strate selection is carried out by the di erent types of E3 ubiquitin ligases10.
Furthermore, deubiquitinating enzymes (DUBs) are part of the ubiquitin-proteasome
pathway mechanism. These enzymes are responsible for removing ubiquitin from targeted
proteins and disassemble polyubiquitin chains11. DUBs add an additional regulatory con-
trol step prior to protein degradation and are responsible for maintaining a free pool of
mono-ubiquitin for protein degradation12.
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Figure 1.1: Overview of the ubiquitin conjugating mechanism. Ubiquitin molecules (Ub, green)
are attached to substrate proteins (purple), which are destined for degradation. Ubiquitination results in
the formation of a bond between the C-terminus of ubiquitin with the e-amino group of a lysine of the
substrate. In the UPS, a well-defined series of enzymes take part in the (poly-)ubiquitination reaction.
Ubiquitin is first activated by the E1 enzyme (pink) under ATP hydrolysis and subsequently transferred
to the E2 conjugating enzyme (turquoise). Next, the E3 ubiquitin ligase (orange) determines the transfer
of ubiquitin to the substrate protein. Here, the transfer varies between the two major classes of E3
ubiquitin ligases, termed HECT and RING-like13,14. The ubiquitin-tagged substrate is then targeted by
the 26S proteasome for degradation (not shown). Ubiquitination is reversed by deubiquitinating enzymes
(DUBs, brown). DUBs remove ubiquitin from proteins and disassemble polyubiquitin chains. Modified
from Ravid and Hochstrasser15.
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1.2 The 20S and 26S Proteasome
1.2.1 The 20S Proteasome - Structure and Function
The 20S proteasome is a large macromolecular complex of approximately 750 kDa, com-
prising 28 subunits arranged in four co-axially stacked heteroheptameric rings (Figure
1.2). The inner rings are formed by seven distinct b-subunits, whereas the outer rings
consist of seven di erent a-subunits. Three b-subunits contain proteolytic active sites
(b1, b2, b5), belonging to the N-terminal nucleophile hydrolase family. These subunits
are located deep within the barrel-shaped structure of the core particle, likely to avoid any
unspecific degradation events and also to maintain a controlled, sequential degradation
of substrates16.
Figure 1.2: Structural details of the 20S proteasome. Top: Side view and cross section of a space-
filling representation of the yeast 20S proteasome (PDB ID: 1RYP)16. Purple dots denote the spatial
position of the b2 (tryptic-like), green dots the b1 (caspase-like), and blue dots the b5 (chymotryptic-
like) active site, respectively. Bottom: Top view on the 20S proteasome. Bottom left: Wild-type yeast
20S proteasome (PDB ID: 1RYP), representing a closed gate. Bottom middle: Opened-gate mutant of
the yeast 20S proteasome (PDB ID: 1G0U)17. Bottom right: View onto the a-ring of the 20S particle
form T. acidophilum, in complex with the PAN C-terminus. The HbYX-motifs (red) which are inserted
into the pockets formed at the interfaces of two adjacent a-subunits are shown. The HbYX motifs bind
to a lysine residue in the a-pocket. Modified from Kriegenburg et al.18
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Each active site cleaves preferentially after particular amino acid residues: (1) The b1 sub-
unit has been classified as a caspase-like active site, because cleavage occurs after acidic
residues, (2) b2 harbors a tryptic-like activity, cleaving after basic residues, and (3) b5 is
termed chymotryptic-like, because cleavage occurs preferentially after bulky hydrophobic
residues19. Studies have determined that the 20S proteasome shows preference for certain
peptide bonds over others for cleavage. The active sites are much less specific with regard
to the recognition of certain amino acid residues in P1 position than classification based
upon fluorogenic peptide substrates would suggest20. According to a model by Schechter
and Berger21, amino acid residues in a substrate undergoing cleavage are designated P1,
P2, P3, P4 etc. in the N-terminal direction from the cleaved bond.
The 20S proteasome has a narrow channel in the center of the outer a-rings that only
allows the passage of unfolded polypeptides, which then access the inner chamber and
proteolytic active sites. The N- terminal tails of the a-subunits form a gate, its closed or
open states prevent or allow the passage of substrates through the channel, respectively
(Figure 1.2)17. To function in vivo, the 20S proteasome needs to associate with regulatory
particles that partially determine the specificity of protease function.
The 20S proteasome is highly conserved from archaea to higher eukaryotes. The striking
features of this protease were structurally analyzed by X-ray crystallography and elec-
tron microscopy. Atomic structures of the 20S proteasome from yeast and mammals have
been determined and their overall structures and subunit arrangements are nearly iden-
tical16,22,23.
X-ray crystallography is a method that enables to gain three dimensional structures of
biological molecules at resolutions below 1 Å. The resolution of a structure measured in
Ångström (Å) is an important indicator towards its quality and reliability. Resolution in
general describes the distance of two points which can be significantly discerned from each
other. To determine a structure’s resolution, one can directly investigate the structural
features (Figure 1.3): Structures around 20 Å show the overall shape. Molecular details
are di cult to interpret in structures between 20 and 10 Å, though proteins and domains
can be assigned. Between 9 and 6 Å alpha helices become visible. Details begin emerg-
ing around 5 Å when secondary structure elements can be determined; b-sheets become
separated and bulky side chains become visible. Starting at 4 Å more side chains appear
in the density. Nucleotide bases start being separated and most side chains are visible at
a resolution of 3.5 Å. In crystal structures resolved to 2 Å, most of the rotamers appear
in their correct conformation and at 1.6 Å the electron density is well enough defined
to see holes in aromatic amino acids. From 1.1 Å resolution, the electron density allows
positions of hydrogen atoms to be resolved.
The first crystal structure of the 20S proteasome was published in 1996 and revealed de-
tails of the Thermoplasma acidophilum 20S proteasome at a resolution of 3.4 Å24. In the
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Figure 1.3: Structural details at distinct resolutions. The atomic model of the 20S proteasome
is filtered to di erent resolutions. The depicted resolutions are defined by features which become visible
in the structure. At 20 Å, the overall shape of the 20S proteasome is recognizable. Individual domains
become visible at 12 Å and at 9 Å the a-helices are structurally defined. Between 6 and 5 Å b-sheets get
separated. Starting at 4 Å, side chains become visible increasingly until at 2 Å all side chains are visible.
following years, 20S proteasomes from yeast (S. cerevisiae)16 and mammals (Bos taurus 23
and Mus musculus 22) were presented at resolutions between 2.4 and 3.2 Å, as well as the
human 20S proteasome structure at 2.6 Å resolution25. Superposition of the individual
catalytic b-subunits revealed that the structures from di erent organisms adopt very sim-
ilar folds. Further, the superpositions of the a-ring of the human proteasome with the
a-ring of the proteasomes from S. cerevisiae, Bos taurus and Mus musculus illustrates
high structural conservation25.
In the crystal structures of free 20S proteasomes from higher organisms, the entrance
to the internal proteolytic chamber containing catalytic sites is usually closed by the N-
terminal tails of the a-subunits16. In yeast, the N-termini of the a1, a2, a3, a6, and a7 fill
the opening in several layers (Figure 1.2). It is assumed that this gate must be opened for
substrate processing in fully activated proteasomes17. Only substantial rearrangements
would allow access of peptide substrates into the catalytic chamber17.
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1.2.2 The 20S Catalytic Mechanism - Proteolysis
Despite the fact that the catalytic sites of the 20S proteasome are unique in their chemical
nature of substrate-binding and substrate preference, all sites employ an identical reaction
mechanism for hydrolysis of the substrates peptide bonds. All three b-type subunits
contain catalytically active threonine residues at their N-termini and employ a N-terminal
nucleophile (Ntn) hydrolase activity.
The catalytic system is formed by the N-terminal threonine (Thr1), providing both the
catalytic nucleophile and the primary proton acceptor, together with Glu17 and Lys33,
first described in T.acidophilum 24,26. With structural and mutational studies it became
clear that the residues Ser129, Ser169 and Asp199 in close proximity to Thr1 are required
for catalysis26,24. Additionally, Groll et al. proposed a fully occupied solvent molecule
(NUK) in all three catalytic sites of the yeast 20S proteasomal complex. This molecule
might be located close to the Thr1 Og and N, Ser129 Og and N and Gly47 N16.
With this knowledge a mechanism for proteolysis was proposed by Groll et al.:
During proteolysis, a nucleophilic attack of the hydroxyl group of Thr1 on the carbonyl
carbon atom of the peptide bond takes place and the first cleavage product and a covalent
acyl-enzyme intermediate are created. Next, the NUK water molecule, localized in close
proximity to the Thr1 acts as a proton shuttle to regenerate the enzyme and the peptide
fragment is released16. The mechanism of substrate proteolysis is depicted as a schematic
representation in Figure 1.4.
Figure 1.4: Substrate proteolysis. Schematic representation of the proteolytic cleavage mechanisms
of the 20S proteasome. The substrates peptide bond is hydrolyzed by the N-terminal Threonine of the
proteolytic active b subunit.
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1.2.3 The 26S Proteasome - Structure and Function
The 2.5 MDa 26S proteasome is a large and complex member of the superfamily of
ATP-dependent "chambered" proteases found in all domains of life27,7. The human 26S
proteasome is a labile complex that can dissociate into the 20S core particle (CP) and the
19S regulatory particle (RP). The 20S particle exhibits the proteolytic activity and the
19S regulatory particle is responsible for substrate recognition, deubiquitination, unfold-
ing and translocation of substrates into the core particle. The regulatory particle consists
of at least 19 subunits, whereby the particle can split into two distinct assemblies: the lid
and the base (Figure 1.5).
The base consists of nine subunits: Rpt1-6 (regulatory particle triple A protein 1-6) are
paralogous AAA+ ATPases and Rpn1, 2, 10 and 13 (regulatory particle non-ATPase)
are non-ATPases. The six RP triphosphatases form a heterohexameric ATPase ring with
the arrangement Rpt1-Rpt2-Rpt6-Rpt3-Rpt4-Rpt528, typically converting ATP hydroly-
sis into mechanical force and being in direct contact with the a-ring of the core particle.
Rpn1 and 2 are the largest subunits of the proteasome, exhibiting a-helical proteasome/-
cyclosome repeats (PC), which function as a docking platform for extrinsic ubiquitin
receptors and deubiquitinating enzymes (DUBs). Rpn13 and Rpn10 directly recognize
and bind ubiquitin, acting both as intrinsic receptors for polyubiquitinated substrates.
With a position in the periphery of the proteasome, the ubiquitin receptors Rpn10 and
Rpn13 sit in a perfect orientation to take part in the first steps of substrate recognition
(Figure 1.5).
The RP lid consists of nine di erent Rpn subunits: Rpn3, 5-9, 11, 12 and Rpn15, whereby
six of them are Proteasome/CSN/Initiation complex (PCI) domains (Rpn3, 5, 6, 7, 9,
and 12). The PCI domain is a purely a-helical domain of approximately 200 amino acid
residues, which is generally localized at the extreme C-terminus of the protein. Rpn8
and Rpn11 are two MPN subunits, forming a heterodimer. The MPN domain spans ap-
proximately 140 amino acid residues present at the N-terminus of the proteins. Both
the PCI and MPN domains might serve as structural sca olds to uphold the protea-
some’s complex structure29. Rpn15 (DSS1 in human) is a small acidic domain involved
in ubiquitin-substrate binding30. Rpn11 belongs to the DUBs. Structurally, the Rpn11
subunit sits above the central pore of the AAA+ ATPase with its catalytic MPN do-
main31. Due to its central position, Rpn 11 might be the primary DUB in proteasome
degradation and is able to cleave o  the entire ubiquitin chain from substrates which
are directed from the 19S regulatory particle to the central pore of the 20S core particle
(Figure 1.5). Mutations of Rpn11 in yeast show that the activity of the domain is linked
to severe growth defects32.
In addition to the 19S proteasomal subunits, a number of proteins associate with the
proteasome via loose, salt-labile interactions. These proteins play important roles in reg-
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ulating the proteolytic function33. Some serve as alternative ubiquitin receptors, such as
the UBL/UBA domain containing proteins Rad23 (radiation sensitive 23), Dsk2 (dom-
inant suppressor of Kar2) and Ddi1 (DNA damage-inducible 1), which help to deliver
specific ubiquitin conjugates to the proteasome34. For example, proteins which trim or
extend the ubiquitin chains of substrates on the regulatory particle are the deubiquitin
enzyme Ubp6/USP14 (ubiquitin-specific protease 6 in yeast and 14 in mammals) and the
ubiquitin ligase Hul5 (HECT ubiquitin ligase 5 in yeast) and its mammalian ortholog,
KIAA1035,36.
Within the 26S proteasome one of the contacts between 20S and 19S particles occurs
through the Rpn5 and Rpn6 lid domains, with their N-termini extended towards the a1
and a2 subunits of the 20S particle31. This allows a direct interaction between the lid and
the core particle. The main contact between 19S and 20S particles was found between the
a-subunits of the 20S and the conserved HbYX (hydrophobic, tyrosine, any amino acid)
motifs at the flexible C-termini of the ATPase domains37. The HbYX regions can dock
at the a3/a4, a1/a2, and a5/a6 pockets between alpha subunits, shown by crosslinking
experiments38. The details of these interactions are not conclusively clarified, but it is
thought that binding of all three HbYX motifs to the a-ring will cause it to undergo a
conformational change that better allows for substrate entry into the proteolytic cham-
ber16,17. In Figure 1.2 the a-ring of the 20S particle form T. acidophilum together with
the inserted HbYX motifs from the PAN C-terminus are shown.
Besides the ATP-dependent activator 19S there are a number of di erent types of "caps"
or activators of the 20S particle. The 11S cap (proteasome activator 28/PA28/REG)
and the bleomycin-sensitive 10 cap (Blm10/PA200), which stimulate the degradation of
substrates without ATP hydrolysis and ubiquitin detection39. The AAA+ ATPase p97
(CDC48/VCP) might also serve as an alternative cap, first shown for proteasomes from
T. acidophilum and later for mammalian proteasomes40,41. Complexes of the 20S core
particle with one 19S regulatory particle on one end and another activator such as 11S
or Blm10 on the other end are reported and referred to as hybrid proteasomes.
In general, the 26S proteasome is a dynamic molecular machine. As a consequence, this
multiprotein complex is biochemically labile or unstable, especially when isolated from
the cell. It is therefore challenging to work with these proteases, either for biochemical
assays or structural studies. Still, during recent years, a series of cryo-EM reconstructions
of the 26S holoenzyme as well as of the isolated RP or lid were published and provide a
much clearer picture of its architecture.
The overall shape of the molecule was observed long ago, but only recently published
structures give insights into the structural arrangements of the subunits within the com-
plex. In 2010, the first subnanometer-resolution structure of the complete 26S proteasome
was presented and individual subunits could be placed into the model42. Only over the
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Figure 1.5: Structure of the 26S proteasome. Upper box: Architecture of the 26S proteasome,
consisting of the 20S core particle, ATPase and Lid-complex. Bottom: Half-top view onto the Lid/ATPase.
Dashed arrow gives the direction of substrate translocation: Substrate is detected by one of the ubiquitin
receptors (Rpn10, yellow) of the lid complex, ubiquitin is recycled by the deubiquitinating lid enzyme
Rpn11 (purple) and enters the 20S core particle by a translocation through the pore of the AAA+
ATPase.
past 4 years several publications revealed the structure of the yeast and human 19S parti-
cle and the 26S holoenzyme at higher resolutions31,43,42,44,45 with recently published struc-
tures of the human 26S proteasome at 3.9, 3.5 and 4.4 Å resolution, respectively46,47,48.
An unexpected feature regarding the core particle and regulatory particle interaction was
found in electron microscopic data of D. melanogaster and S. pombe 26/30S proteasomes:
The pore of the heteroheptameric AAA+ ATPase ring of the regulatory particle does not
align with the pore of the 20S core particle. It is shifted axially by almost 30 Å and tilted
vertically by 5-10¶ 49. The functional significance of the disalignment was not known, but
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recent structural data from the yeast proteasome o ers an explanation for this o set.
Three major conformational states of the proteasome holoenzyme have been found by
cryo-EM analysis: S1, S2 and S350. These states form the basis for a hypothesis of ubiq-
uitin/substrate binding, deubiquitination, substrate unfolding and translocation by the
proteasome. S1 is defined as the ground state, which is the predominant state under ATP
hydrolysis and without substrate present in the condition. In contrast, the S3 state is
present upon excess of substrates51 or by introducing the non-hydrolyzable ATP ana-
logue ATPgS50 to the system. S2 is a hybrid state between S1 and S3. It is proposed
that docking of substrates occurs in the S1 state, considered the substrate-accepting state,
followed by a structural rearrangement when the substrate is accepted for degradation
in S2 state. Finally, the substrate is unfolded, ubiquitin is removed and the substrate is
translocated into the 20S core particle for degradation in conformational state S3, the
substrate-processing state. The main conformational rearrangements are a rotation of the
lid by 25¶ and a translation and rotation of the AAA+ ATPase in relation to the 20S
core particle, resulting in an alignment of the ATPase ring and the core particle channel
in S3.
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Table 1.1: 26S proteasome subunits. Listed are all subunits belonging to the core and regulatory
particle of the 26S proteasome.
Subunit Subcomplex Function Activity/domain
Name
a1 20S core particle Sca olding/gating
a2 20S core particle Sca olding/gating
a3 20S core particle Sca olding/gating
a4 20S core particle Sca olding/gating
a5 20S core particle Sca olding/gating
a6 20S core particle Sca olding/gating
a7 20S core particle Sca olding/gating
b1 20S core particle Protease Caspase-like
b2 20S core particle Protease Tryptic-like
b3 20S core particle Sca old
b4 20S core particle Sca old
b5 20S core particle Protease Chymotryptic-like
b6 20S core particle Sca old
b7 20S core particle Sca old
Base
Rpt1 19S regulatory particle Unfoldase AAA+ ATPase
Rpt2 19S regulatory particle Unfoldase AAA+ ATPase
Rpt3 19S regulatory particle Unfoldase AAA+ ATPase
Rpt4 19S regulatory particle Unfoldase AAA+ ATPase
Rpt5 19S regulatory particle Unfoldase AAA+ ATPase
Rpt6 19S regulatory particle Unfoldase AAA+ ATPase
Rpn1 19S regulatory particle Substrate recruitment PC repeats
Rpn2 19S regulatory particle Rpn13 docking PC repeats
Rpn10 19S regulatory particle Ubiquitin receptor vWA/UIM domain
Rpn13 19S regulatory particle Ubiquitin receptor PRU domain
Lid
Rpn3 19S regulatory particle Ubiquitin receptor PCI domain
Rpn5 19S regulatory particle Ubiquitin receptor PCI domain
Rpn6 19S regulatory particle Ubiquitin receptor PCI domain
Rpn7 19S regulatory particle Ubiquitin receptor PCI domain
Rpn8 19S regulatory particle Ubiquitin receptor JAMM/MPN+ domain
Rpn9 19S regulatory particle Ubiquitin receptor PCI domain
Rpn11 19S regulatory particle Deubiquitinylation JAMM/MPN+ domain
Rpn12 19S regulatory particle Sca old PCI domain
Rpn15 19S regulatory particle Ubiquitin receptor IDP
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1.3 Proteasome Inhibition
The proteasome is a key molecular complex for the degradation of proteins that control
the cell division cycle and apoptosis. It is therefore an interesting target for therapeutic
agents that inhibit cell proliferation in diseases such as cancer. Proteasome inhibition is
an accepted antineoplastic strategy since the approval of Bortezomib in 200352. Within
nine years, Bortezomib was raised from development to its first approval by the US Food
and Drug Administration (FDA) for the treatment of multiple myeloma, with an annual
sales value of two billion US Dollars. The success of Bortezomib has drawn further inter-
est in proteasomes as targets in oncology, and today at least five other compounds are at
various stages of clinical approval for treatment of multiple myeloma, a cancer of plasma
cells53,54.
Inhibition of proteasomes leads to the accumulation of misfolded proteins and the forma-
tion of toxic, reactive oxygen species. At the same time it induces apoptosis in cancerous
cells, which lack the ability to enter cell cycle arrest55. In preclinical studies, researchers
studied the e ectiveness of proteasome inhibitors on di erent types of cancers and found a
selectivity for malignant cells56,57. It was found that actively proliferating malignant cells
are more sensitive to proteasomal inhibition than non-cancerous cells58,59. The underly-
ing mechanisms of the increased susceptibility of malignant cells are not yet completely
understood. Malignant cells have characteristics that might play a role in the biological
basis for this cytotoxic mechanism: malignant cells proliferate rapidly and have therefore
an increased demand for proteasomal degradation. This hypothesis is consistent with
findings in studies of lymphocytes. Chronic Lymphocytic Leukemia (CLL) lymphocytes
have a three-fold higher activity of the chymotryptic-like active site and an upregulated
ubiquitin-proteasome system with higher levels of ubiquitin-conjugated proteins com-
pared to healthy lymphocytes60. Inhibition of the proteasome in cancerous lymphocytes
would result in an accumulation of proteins and terminate in apoptosis.
The first clinically approved drug Bortezomib revealed substantial o -target activity by
reacting with various enzymes that results in severe side e ects61. Furthermore, resistance
to this drug remains a clinically significant problem62. In recent years, second-generation
competitive inhibitors have been discovered and many are under evaluation by the FDA.
The design principle for these inhibitors involves a combination of a peptide moiety
coupled with a reactive head group acting as electrophilic anchor, such as for example
a’,b’-epoxyketones, boronates, aldehydes, a-ketoaldehydes, vinyl sulfones or b-lactones.
Most of the recently published structural knowledge about proteasome inhibition includ-
ing the mechanism of inhibitor binding and the binding-site composition derives from
studies of the yeast 20S proteasome. Only little is known about the inhibitory mecha-
nisms in the human system, whereas it is assumed that inhibition takes place in a similar
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manner. The first structures of the human 20S proteasome in complex with inhibitors
were only recently determined by X-ray crystallography and electron microscopy at res-
olutions of 2.9 Å and 3.5 Å, respectively25,63. Due to the relatively low resolution of
these structures, direct observations of atomic details, especially at the binding site of
inhibitors, was not possible. Nevertheless, predicted models for the inhibition mechanism
of various inhibitor classes were published and are presented in the following sections.
Structures of di erent 20S proteasome-inhibitor complexes were elucidated and analyzed
for this thesis. Numerous inhibitors are described in literature, but only a selection of
inhibitor classes was investigated in this thesis (Figure 1.6). In the following, the rele-
vant inhibitor classes are listed and briefly described: 1) Boronic acid inhibitors, includ-
ing the Bortezomib inhibitor with a lead in anti-cancer therapy over the last years, 2)
Epoxyketone inhibitors that are a highly potent and customizable class of inhibitors, and
3) a-Ketoaldehydes, which were discovered in the 1990s but neglected for several years
because their benefit over other inhibitor classes was not understood at that time.
Figure 1.6: Chemical structures of proteasome inhibitors. Chemical structures of the boronic
acid inhibitors Bortezomib, Ixazomib and Delanzomib. Oprozomib, Dihydroeponemycin and Epoxomicin
belong to the group of a,b-epoxyketone inhibitors. Z-LLY-Ketoaldehyde represents the a-ketoaldehyde
inhibitors.
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1.3.1 Boronic Acid Inhibitors
Bortezomib, along with other boronic inhibitors is highly potent and inactivates the
proteasomal active site by a covalent but slowly reversible binding mode. Boronic acid
inhibitors covalently react with the nucleophilic Thr1Og of the 20S proteasome proteolyt-
ically active subunits. Bortezomib was developed after successful proteasome inhibition
was shown for the natural agent lactacystin and synthetic aldehyde inhibitors. Borte-
zomib is based on the substitution of the aldehyde with boronic acid to gain a compound
which forms a covalent, reversible complex and exhibits an improved selectivity for pro-
teasomal active sites compared to corresponding aldehydes64.
Bortezomib was the first proteasome inhibitor to enter clinical trials and to be approved
for cancer therapy, but despite prolonging the lifetime of multiple myeloma patients,
Bortezomib shows severe side e ects like neuropathy. In addition, patients often develop
resistance and treatment requires an intravenous or subcutaneous injection, which is not
ideal. Still, the positive clinical outcome of Bortezomib treatment provided a motivation
for the discovery and development of next-generation proteasome inhibitors with higher
e ciency and enhanced tolerability.
One of the next-generation boronic acid inhibitors is an orally bioavailable proteasome
inhibitor, Ixazomib (MLN2238). Approved by the FDA in 2015, Ixazomib is used for the
treatment of multiple myeloma patients with selectivity and potency similar to that of
Bortezomib. This reversible proteasome inhibitor preferentially binds to and inhibits the
b5 active site of the 20S proteasome, whereby at higher inhibitor concentrations Ixazomib
also inhibits the b1 and b2 activity65,66.
A third boronic proteasome inhibitor, Delanzomib (CEP-18770), is currently in clinical
trials. Delanzomib is orally deliverable and has been investigated in Phase I clinical trials
for treatment of solid tumors, leukemia and non-Hodgkin’s lymphoma67. Delanzomib was
developed to inhibit the b5 chymotryptic-like site of the proteasome68. However, it also
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1.3.2 Epoxyketone Inhibitors
The epoxyketone class of inhibitors are known for their specificity and potency, with no
evidence of o -target e ects. The first structural analysis of epoxyketone inhibition was
carried out in S. cerevisiae 20S proteasomes. These studies proposed a possible mode of
proteasome inhibition by the epoxyketone inhibitor Epoxomicin70. The inhibitor binds
to the Thr1 in the b5, chymotryptic-like active site by a formation of a six-membered
morpholine ring linkage. The morpholine 6-ring structure formation is described as a
2-step process (Figure 1.8). First, activation of the Threonyl Og occures either via the N-
terminal group of Thr1 or via a neighboring water molecule found in all active sites of the
20S proteasome. A nucleophilic attack of the Thr1Og on the a,b-epoxyketone’s carbonyl
carbon forms a hemiacetal. Next, the free a-amino group of Thr1 opens up the epoxide
ring and intramolecular cyclization takes place. The resulting 1,6-morpholino ring closure
is formed, irreversibly inhibiting the active site.
Carfilzomib and its orally bioavailable analog ONX-0912 are two a’,b’-epoxyketone in-
hibitors that are approved or in clinical trials by the FDA, respectively71. Carfilzomib
is equally potent to the boronic acid inhibitor Bortezomib but more selective for the
chymotryptic-like site of the catalytic core. The specificity and relatively simple synthe-
sis made epoxyketone inhibitors a popular choice for the synthesis of many modifica-
tions with the result of hundreds of epoxyketones, including many subunit-selective and
activity-based inhibitors72.
Figure 1.8: Mechanism proposed for a,b-epoxyketone inhibitors. Schematic representation of
the proposed inhibition mechanism of a,b-epoxyketone inhibitors.
1.3.3 Ketoaldehyde Inhibitors
a-Ketoaldehyde inhibitors were first discovered in 1990, but only in 2011 first structural
studies of the yeast 20S proteasome in complex with a ketoaldehyde revealed details
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about the mode of action73. Similar to epoxyketone inhibitors, a ring structure is formed
upon inhibition, but unlike epoxyketones, the binding of an a-Ketoaldehyde is proposed
to result in a 5,6-dihydro-2H -1,4-oxazine ring closure including a hemiketal and an imine
bond (Schi  base). Formation of the hemiketal after the nucleophilic attack of Thr1 Og
proceeds as described for epoxyketone inhibition, but the second step encompasses a
nucleophilic attack on Thr1N on the aldehyde carbon and a formation of a tetrahe-
dral carbinolamine before releasing a water molecule and forming the rigid 6-membered
ring. All steps towards the ring-formation are reversible, giving this class of inhibitors
completely di erent pharmacological properties than those of irreversible epoxyketone
morpholine-linkage inhibitors.
Figure 1.9: Mechanism proposed for a-ketoaldehyde inhibitors. Schematic representation of the
proposed inhibition mechanism of a-ketoaldehyde inhibitors.
1.3.4 Recent Advances in Proteasome Inhibitor Development
Most of the proteasome inhibitors which are currently used as chemotherapeutics, or are
in development are peptide-based covalent inhibitors. These compounds exert their in-
hibitory activity by a covalent interaction with the active site Thr1 Og of the b-subunit.
Covalent inhibitors are highly reactive, which leads to o -target interactions. In addition,
the tissue distribution is very low due to slow dissociation kinetics, often inducing apop-
tosis and cell death in vivo of non-cancerous cells74,75.
To overcome the disadvantages related to covalent inhibition, a concerted e ort was put
into development of noncovalent proteasome inhibitors, which bind the proteasome re-
versibly and time-limited. A number of classes of substrate-competitive and noncovalent
proteasome inhibitors were identified and tested. These classes include Benzylamides,
Oxadiazoles, and various natural products76,77,78,79,80,81. For the development of new
peptide-based noncovalent inhibitors extensive work has been carried out: New inhibitors
were synthesized based on high-throughput screening of libraries including several hun-
dred thousand compounds82.
In 2000, scientists discovered the natural product TMC-95A and its diastereomeres B, C
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and D from Angiospora montagnei, TMC-95A demonstrated a selective and competitive
inhibition of the proteolytic activity of the 20S proteasome in a low molecular dose83,80.
These natural products were characterized as novel cyclic peptides, consisting of a het-
erocyclic ring system. TMC-95A inhibits all three catalytic sites of the 20S proteasome,
shown by crystallographic studies84. The mode of inhibition was described as noncovalent
without modification of the N-terminal threonine upon inhibition. This noncovalent in-
hibitor binding is carried out by a specific network of hydrogens bonds. These interactions
are between strictly conserved residues of the active sites with main-chain atoms of the
inhibitor. TMC-95A adopts an antiparallel b-sheet structure with the peptide backbone
as previously reported for a’,b’-epoxyketone and aldehyde inhibitors16,24,80,83. TMC-95A
is favored over flexible ligands because its rigid ring structure prevents the inhibitor from
structural rearrangements upon binding.
Currently many details of proteasome inhibition are known and a number of selective
and potent inhibitors have been synthesized. A drug candidate with the optimal char-
acteristics has not yet been found or produced. Results from biological assays as well as
structural studies will help to improve existing inhibitors or to design new compounds
that may provide better chemotherapeutic treatment solutions in the future.
1.3.5 Biological Implication of Proteasome Inhibition
Many cellular pathways are dependent on correct proteasome function. Several proteaso-
mal substrates have essential tasks in cell-cycle regulation. Processing of these substrates
by the proteasome are therefore essential. Important complexes involved in cell-cycle
progression that depend on proteasome function are the cyclin-dependent kinase (CDK)
complexes. CDK activity is regulated by short-living proteins, namely cyclins, which act
at various stages of the cell cycle. The rapid turnover of cyclins is carried out by the UPS
and only by an ordered and timed degradation of these small regulators can the continued
growth of cells be sustained85,86. Inhibition of the proteasome-mediated degradation of
the cyclin proteins therefore results in reduced cell growth.
Furthermore, the proteasome controls apoptosis by a ecting the nuclear factor of kB
(Nf-kB). Nf-kB transcription factors are bound to a specific inhibitor protein, IkB, inac-
tivating it and preventing it from activating transcription of its target genes. Upon stress,
such as chemotherapy, radiation, viral infection and growth factors, IkB is phosphory-
lated and subsequently degraded by the 26S proteasome87,88, releasing Nf-kB. Nf-kB then
translocates from the cytoplasm into the nucleus to activate transcription of a series of
factors that promote cell growth and di erentiation, and prevent apoptosis. Importantly,
Nf-kB initiates its own transcription and the transcription of its inhibitor IkB, maintain-
ing its own activity by positive feedback57. By an inhibition of the proteolytic activity
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of the proteasome, IkB is stabilized in the cell and cancer cells are more vulnerable to
chemotherapeutic or radiation treatments.
Proteasome function also influences the activation of the tumor suppressor p5389. p53 is
a short-lived protein with low quantities in the healthy eukaryotic cell. Cellular stresses
such as chemical- or radiation-induced DNA damage, oxidative stress or oncogene ac-
tivation cause p53 to accumulate in the cell, which triggers diverse cellular responses
such as cell-cycle arrest. The cell e ciently regulates the cellular stress response by a
feedback regulation via the p53-induced expression of MDM2 which then transports p53
from the nucleus to the cytoplasm and ubiquitinates p53 for rapid proteasomal degrada-
tion90. Upon proteasome inhibition, p53 becomes activated and stimulates p53-mediated
tumor-suppressor activity that result in apoptosis and senescence.
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1.4 An Introduction to X-ray Crystallography and
Single Particle Electron Cryomicroscopy
Understanding the chemical and biological functions, and mechanisms of macromolecular
complexes often requires structural data with details at atomic resolution. Developments
in technology and methodology over the last 20 years have paved the road to narrow the
gap between two e ective methods to study the structure of macromolecular machines:
X-ray crystallography and single particle electron cryomicroscopy. In the present thesis
both methods were utilized to analyze proteasome inhibition of either the 20S proteasome
or the 26S holoenzyme. In the following section, a short introduction to both techniques
is provided and the advantages and disadvantages of the techniques is presented.
1.4.1 X-ray Crystallography
X-ray crystallography is by far the oldest technique to investigate the structures of single
molecules as well as macromolecular complexes. The discovery of X-rays by Wilhelm Con-
rad Roentgen in 1895 lead the way to its application in crystallography in the beginning
of the 20th century and its first application in synchrotron radiation in the mid-1970s91.
In 1958, John Kendrew unveiled the first protein structure, the structure of Myoglobin, a
milestone in the history of structural biology92. Only two years later, Perutz published the
structure of Hemoglobin93. These milestones were achieved because a group of crystallo-
graphers around Perutz discovered the "method of isomorphus replacement" by which for
the first time the crystallographic phase problem was overcome. Perutz discovered that
heavy atoms could be attached to protein molecules and by this, the di raction pattern
would di er from crystals without heavy atoms. With this, phases of the reflections could
be inferred for the first time94,95.
In di raction experiments, intensities of waves scattered from planes in the crystal are
measured. The amplitude of the wave is proportional to the square root of the intensity
measured on the detector. To calculate the electron density at a position in the unit cell,
a summation of all planes is performed. Here, a certain electron density is the sum of
contributions to the point of waves scattered from a plane, whose amplitude depends on
the number of electrons in the plane, added with the correct relative phase relationship.
This can be written mathematically as:
p(xyz) = 1/V
ÿ
|Fhkl|exp(i–hkl)exp(≠2fiihx + ky + lz) (1.1)
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where V is the volume of the unit cell, hkl is the crystal plane, the position in the unit
cell is described as xyz and ahkl is the phase associated with the amplitude |Fhkl|96. The
amplitudes can be measured but the phases are lost, which is known as the "phase prob-
lem".
For successful data collection a combination of the best possible instrumentation and a
data collection strategy is needed. Today, di raction patterns are measured at modern
beamlines in synchrotron facilities with a very strong beam intensity, resulting in short
exposure times. Data sets are collected with the oscillation photography method. The
axes of the crystal are carefully aligned to the beam based on pre-screening of the crystal
and the crystal is rotated around the set oscillation axis with di raction patterns col-
lected at defined angular distances.
Di raction of protein crystals relies almost exclusively on scattering of X-rays by the
electrons in the molecule resulting in spots measured on the detector during data col-
lection. These spots have to be interpreted and incorporated into an overall dataset by
scaling and merging. The amplitudes of interfering X-ray waves can be identified and the
unit cell dimensions, crystal symmetry, and information of the molecular packing can be
determined from the di raction pattern intensities.
For calculating an electron density map, phase information has to be obtained. In addi-
tion to the method of isomorphus replacement introduced by Perutz, several experimental
procedures to phase observed structure factor amplitudes were developed. One common
way to determine phases is molecular replacement97. Here, for example a reasonable ho-
mology model, can be used to provide an initial estimate for the phases. Besides this,
a number of "direct methods" exist. Ab initio phasing is used when no phases from a
structurally similar model are available, or if one wants to circumvent any kind of model
bias by molecular replacement. To date, a standard ab initio method is still the Single
or Multiple Isomorphous Replacement (SIR, MIR) method. Here, di raction data from
the native crystal and one or more crystals with derivatives, which produces a di erent
di raction pattern, is collected98. Another approach is Single and Multiple Anomalous
Dispersion (SAD, MAD)99,100. Data is collected from a single crystal at several wave-
lengths, one wavelength at the absorption peak, one at the point of inflection and one
at a remote wavelength. Whereas with SIR and MIR the protein phases are estimated
from the additional scattering of the heavy metal atom crystals, in SAD and MAD the
phases are calculated from wavelength-dependent quantitative di erences in the anoma-
lous scattering contribution of certain atoms contained within crystals.
Previously it was shown that phases for macromolecular complexes could be solved with
anomalous scattering. The 30S ribosomal subunit from B. Stearothermophilus was solved
by using the heavy atoms, osmium and lutetium at 5.5 Å resolution101. Similarly the
fully assembled T. thermophilus 70S ribosome was phased with the anomalous scatterer
iridium and solved to 7.8 Å resolution102.
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Concluding the general X-ray crystallographic workflow, the determination of the ini-
tial phases is followed by the refinement of the phases, ending with a correct structural
model. A model of the molecule is then built that agrees with both the information from
di raction in addition to biochemical knowledge.
Until today, X-ray crystallography has become the dominating method to determine
three-dimensional structures of biological macromolecules. Synchrotron facilities that pro-
vide brilliant X-ray sources have extremely fast data-collection times and highly developed
crystallographic methods form the basis to study macromolecules at very high resolution.
Besides data collection and interpretation, one step for determining a three dimensional
structure is fundamental: the crystallization of protein. The outcome of the crystalliza-
tion procedure is determined by the choice of sample, optimization of the crystallization
condition and post-crystallization treatments.
For the crystallization of macromolecular samples, the choice of the sample is often deter-
mined before starting with sample purification, or while searching for a suitable purifica-
tion protocol. The initial step for crystallization is done when a reproducible purification
strategy for the sample of choice is found and the soluble macromolecule can be prepared
in viable quantities. For crystallization, the sample is then transferred into a solution,
called mother liquor, in which it forms crystals. Finding a crystallization condition in
which the flexible macromolecules arrange themselves in an ordered fashion can take
time and often results in protein crystals which are fragile and need a complex post-
crystallization treatment. Crystallization trials are performed in conditions that vary in
bu er substance, pH, ions and precipitants. Besides the crystallization solution a number
of factors are decisive for the optimal crystallization condition, including sample con-
centration, temperature and crystallization method. Most protein crystals are produced
by the vapour di usion method, either in hanging or sitting drop crystallization plates
at temperatures ranging from room temperature (20-25¶C) to temperatures close to the
freezing point of water (0 ¶C). The setup for the vapour di usion methods is relatively
simple: A drop containing the protein sample is equilibrated against a large reservoir of
mother liquor. Volatile substances can then di use between drop and reservoir, reaching
an equilibrium in which the protein will crystallize. The absence of crystals and a clear
drop indicates that the equilibration is still ongoing or the sample concentration is too
low. When the drop shows precipitate but no crystals, the sample concentration might
be too high. The protein crystals obtained are mostly fragile and/or they contain ordered
molecules but also disordered solvent in between. The crystal volume occupied by sol-
vent molecules is at about 40-60 % depending on the crystal103. With post-crystallization
treatments the volume of solvents can be reduced, and the crystal lattice becomes more
ordered or the packing is more dense. This can even change the crystallographic space
group. These rearrangements reinforce and form new crystal contacts, resulting in better
di racting crystals. The most e ective post-crystallization protocol must be evaluated for
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every crystal condition. Mostly it encompasses an increase or introduction of precipitant
and/or the addition of small molecules which stabilize the crystal internally. Crystal de-
hydration can lead to remarkable improvements in crystal di raction104.
Since collection of X-ray data is carried out using a high intensity beam, the energy can
cause severe heating and radiation damage on the crystal. To increase the lifetime of
crystals in the X-ray beam it is an advantage to cool the crystals to very low temper-
atures (100 K/ -173 ¶C), the crystals must be protected from ice formation by using
cryo-protectants. These cryo-protectants include Glycerol, MPD, low molecular weight
PEGs and oils. The crystals are transfered to the cryo-protectant for varying time spans
between a few seconds and hours. The crystals are then frozen in liquid nitrogen (lN2)
prior to X-ray measurements. An overall workflow of X-ray crystallography is presented
in Figure 1.10.
1.4.2 Single Particle Electron Cryomicroscopy
Electron microscopy is the youngest among all other methods to determine three dimen-
sional structures of protein complexes. In 1872, Ernst Abbe formulated his wave theory
of microscopic imaging and about 60 years later the first electron microscope was built
by Ernst Ruska and Max Knoll105. Historically, electron microscopes were developed to
overcome the limited resolution in light microscopes, imposed by the wavelength of vis-
ible light. Due to the small wavelength of electrons electron microscopes are capable of
imaging at a higher resolution.
Using electron microscopy, a broad specimen range from the atomic to tissue scale objects
can be imaged, providing snapshots of biological samples and cells close to their native
states. For isolated macromolecular complexes the method of choice is the single particle
electron cryomicroscopy approach using a transmission electron microscope (TEM). The
TEM has a very similar setup to a light microscope, whereby the image is formed by
transmitting electrons and not light. Those electrons interacting with the sample con-
tribute to a phase contrast image, the electron micrograph. Phase contrast imaging is the
highest resolution imaging technique ever developed, and can allow for resolutions of less
than 1 Å.
Macromolecular machines are important in all living cells and with improving imag-
ing and image processing methods, electron microscopy is now a standard technique to
study macromolecular assemblies. The method became popular when it was possible to
structurally study macromolecular complexes which are resistant to crystallization, al-
beit at lower resolution. Over the years, technological advances in sample preparation,
instrumentation and computational analysis made electron microscopy a benchmark for
structural studies.
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Structural investigation of macromolecular complexes starts with a specialized sample
preparation method. The purified protein sample is usually applied to an EM grid cov-
ered with a thin holey carbon film and blotted by a filter paper to remove excess solution
to form a thin liquid layer. The sample is then rapidly vitrified in liquid ethane106 to
bring all particles to a solid state and to prevent dehydration within the vacuum of an
electron microscope. Freezing also reduces the e ects of electron beam damage107. Next,
the images, called electron micrographs, are collected to capture 2-dimensional projec-
tions of single particles in spacial orientations. Due to low dose exposure to reduce beam
damage, the 2D micrographs have a poor image contrast. To reduce the noise, a high
number of individual particles in the same orientation are averaged using software that
aligns and merges the data. An initial 3D volume is constructed from many averaged
images and the map is then iteratively refined and validated to become the final 3D map.
Subsequently, the model is built and the quality of the map is then evaluated.
Recent technical advances in single particle cryo-EM allow structures of macromolecular
machines to be determined in the resolution range between 2.5 to 5 Å. For example,
ribosomes from human pathogens108 or ribosome-protein complexes provide insight to
their functions. Simultaneously, technical improvements in cryo-EM led to structures of
smaller complexes with molecular masses smaller than 200 kilodaltons (kDa) to be de-
termined109. An idealized single particle electron cryomicroscopy workflow is presented
in Figure 1.10.
1.4.3 Advantages and Disadvantages
In the last years, the major advances achieved in all aspects of structural biology are
numerous. Sample preparation, crystallization, access to synchrotron facilities, high-end
microscopes and high-speed computing enable multiple solutions to gain structural in-
formation of many microscopic objects. Working with X-ray crystallography and single
particle electron cryomicroscopy means working with two di raction-based techniques
that bring along their own benefits and limitations.
A decisive factor when comparing these two techniques is the sample amount. For many
protein complexes scientists struggle to purify large quantities, because the sample is
labile or the purification protocol is not mature. For EM, only relatively low amounts
of sample are needed, whereas crystallization often requires amounts in the milligram
quantity range.
Both X-ray and electron beams cause radiation damage to biological samples. In X-ray
crystallography some crystals tolerate high total doses because of their size and/or pack-
ing within the crystal. In EM, the total electron dosage to image the single particles has
to be set to a minimum to preserve the structural information. As a consequence, low
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dose imaging results in a poor signal-to-noise ratio making it is di cult to obtain good
quality data.
X-ray di raction reveals its major limitation when studying macromolecular complexes:
crystallization of dynamic complexes is challenging and phasing represents the common
bottleneck in crystallography. Even with outstanding samples, a successful analysis by
X-ray crystallography is limited by the production of crystals and finally by the crystal
quality which is still a trial and error approach. Nevertheless, in the last ten years an
unprecedented increase in the number of new crystal structures in the Protein Database
(PDB) is apparent.
Electron cryomicroscopy is suitable for large (>100 kDa) macromolecular complexes.
Cryo-EM often struggles with problems in image analysis, which is mostly dependent on
the sample quality. However, electron cryomicroscopy represents a powerful tool to study
the structure and dynamics of macromolecular complexes at intermediate resolutions be-
tween 10 and 30 Å, while resolutions around 3 Å can also be achieved. The resolution
limit around 3 Å was reached with macromolecular machines like polymerases, ribosomes
and viruses from various organisms.
Moreover, hybrid structural approaches are also common. Cryo-EM and X-ray crystallog-
raphy are complementary techniques; often atomic models from crystallographic studies
are combined with electron microscopic data at medium resolution.
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Figure 1.10: The overall X-ray crystallography and single particle cryo-EM workflow, from
protein sample to 3D model. Schematic figure showing the workflow for macromolecular structure
determination by X-ray crystallography and Cryo-EM. (1) X-ray crystallography: Di raction images are
obtained from protein crystals. These images encode the structural information. With the help of Fourier
transformations, the information is translated into the molecular real space. Since the phases are not
directly accessible so-called phasing approaches have to be performed. With further experimental data
or by molecular replacement calculations these phases are obtained. Once initial phases are obtained,
electron density maps are calculated. Molecular model building and structural refinement form the final
steps of x-ray crystallographic model building. (2) Cryo-EM: A single-particle project starts with spec-
imen preparation and the collection of EM images. The single particles are isolated and 2D analysis is
performed. Next, an initial 3D map is calculated and iteratively refined. The final map is used to build
a 3D model of the macromolecule.
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1.5 Objectives
The aim of this thesis is to structurally characterize the inhibition of the human protea-
some. During the course of this thesis, special attention was paid to the development of
new methods and improvement of known methods to find ways for screening and char-
acterizing the inhibition of the human 20S and 26S proteasome.
To elucidate structures of the human 20S proteasome, a reproducible, large-scale method
to purify proteasomes from HeLa cytoplasmic extract was needed. Hence, a great e ort
was spent on the development of a gentle, chromatography-free purification strategy for
human proteasomes. A robust pipeline for the production and crystallization of human
20S proteasomes could be established. The crystallization procedure reproducibly yielded
20S proteasome crystals in high abundance and allowed the analysis of native human 20S
proteasome and in complex with cancer therapeutics in greater detail.
In the second part of this thesis, the structural implications of 20S core particle inhibition
on the human 26S holoenzyme were studied. The novel purification strategy was trans-
ferred to human 26S proteasomes, yielding high amounts of 26S proteasome complexes.
Structures of human 26S proteasomes with and without inhibitors were analyzed by sin-
gle particle electron cryomicroscopy and the structural di erences were investigated. The
visualization of changes in the structure of the human 26S proteasome upon drug binding
then allowed to formulate a hypothesis for future proteasome inhibitor design.





Table 2.1: Software used in this thesis.
Software Source
Amira 4.1 https://www.fei.com/software110
Adobe Creative Suite 5 http://www.adobe.com/de/creativecloud.html
CCP4 http://www.ccp4.ac.uk
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2.1.2 Special Equipment
Table 2.2: Machines and special equipment used in this thesis.
Machine/Equipment Manufacturer
ActiLoops Molecular dimensions
Äkta Prime GE Healthcare
Balances Sartorius
Centrifuge LYNX 6000 Thermo Scientific
Copper EM grids Plano
Cryschem M Plate, 24-well Hampton Research
Crystal Clear Sealing Tape Jena Bioscience
Crystalgen Plate 24-well, pregreased Jena Bioscience
Fiberlite rotor F14, F21, F35L Thermo Scientific
FluoroMax-4 fluorescence spectrophotometer Horiba Scientific
Gradient Master ip Biocomp
Incubator Eco-Line E100 RUMED
Incubator Multitron Pro Shaker Infors HT
Leica EM GP Leica
LithoLoops Molecular dimensions
Micro-Ultracentrifuge MX 150+ Sorvall
Orbital Shaker RS0S20 Phoenix Instrument
Photometer Lambda Bio X Perkin Elmer
Plate Sealer ALPS 3000 Thermo Scientific
Pipetting Robot Microlab Star LET Hamilton
Quantifoil grid R3.5/1 Cu 200 mesh Quantifoil Micro Tools GmBH
Rotor TH660 Sorvall
Rotor S140AT Thermo Scientific
Rotor SW40 Beckmann Coulter
Siliconized Glass Cover Slides Hampton Research
Stereo microscopes M125 Leica
TEM CM200 FEG Philips
TEM Titan Krios FEI
Ultracentrifuge WX Ultra 80, 90 Sorvall
Vitrobot FEI
Zebra Micro Desalt Spin Columns Thermo Scientific
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2.1.3 Chemicals





b-Gycerophosphate disodium salt hydrate Sigma-Aldrich
Benzamidine Hydrochloride hydrate Sigma-Aldrich
Bis[sulfosuccinimidyl] suberate (BS3) Thermo Scientific
Bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methan Sigma-Aldrich
Bovine serum albumin (BSA) Sigma-Aldrich
Bradford Assay reagent BioRad
Coomassie Brilliant Blue R-250 BioRad
Dimethylsulphoxide (DMSO) AppliChem
Dinatriumhydrogen phosphate (Na2HPO4) Merck
Dipotassium phosphate (K2HPO4) Merck
Ethanol Merck










Octyl Glucose Neopentyl Glycol Anatrace
Phosphoenolpyruvic Acid Tris(cyclohexylammonium)
Salt Hydrate TCI
Polyethylene glycol (PEG) 400 Sigma-Aldrich
Polyethylene glycol (PEG) 3350 Sigma-Aldrich
Potassium chloride Merck
Potassiumdihydrogen phosphate (KH2PO4) Merck
Protamin sulphate Sigma-Aldrich
Protease inhibitor tablet , EDTA free Roche
Protein Marker BioRad




SDS-PAGE running bu er Roth
Sulfo-MBS Thermo Scientific













Table 2.4: Bu ers for protein purification, crystallization, crystal stabilization/dehydration
and enzymatic assay. Composition of all bu ers used for the experiments listed in this thesis.
Purpose Composition
Purification 0.05 M BisTris pH 6.5, 0.05 M KCl, 0.01 M MgCl2,
0.01 M b-Glycerophosphate
Crystallization 0.1 M BisTris pH 6.5, 0.2 M MgCl2, 10 % (w/v) PEG3350
Crystal stabilization 0.1 M BisTris pH 6.5, 0.2 M MgCl2, 20 % (w/v) PEG3350
Crystal dehydration 0.1 M BisTris pH 6.5, 0.2 M MgCl2, 25 % (w/v) PEG3350,
20 % (v/v) MPD
Enzyme activity 0.05 M BisTris pH 6.75, 1 mM EDTA, 0.01 % (w/v) SDS
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2.2 Methods
2.2.1 Protein Purification
2.2.1.1 Purification of 20S Proteasomes from HeLa cells
S30 HeLa cytoplasmic extract was prepared by hypotonic lysis according to Dignam et
al.118, with some minor modifications: after hypotonic lysis and centrifugation to collect
nuclei, the supernatant (the crude cytoplasmic extract) was centrifuged at 30.000 x g for
30 minutes at 4 ¶C and flash frozen in 40 ml aliquots in liquid nitrogen and stored at
-80 ¶C until further use.
The S30 HeLa cytoplasmic extract was thawed in a water bath at 37 ¶C, supplemented
with purification bu er to 1x concentration from a 10x stock, followed by the addi-
tion of sucrose powder to 20 % (w/v), Octyl Glucose Neopentyl Glycol (OGNG; from
a 10 % (w/v) stock solution in water) to 0.1 % (w/v), Iodoacetamide to 10 mM, N-
Ethylmaleimide to 10 mM and Benzamidine Chloride to 10 mM. The extract was incu-
bated at room temperature on a magnetic stirrer for 30 minutes, followed by incubation
at 30 ¶C with shaking at 140 rpm for 1 hour. The treated extract was centrifuged at
100.000 x g for 2 hours at 4 ¶C. After centrifugation, the supernatant was filtered through
3 layers each of cheese cloth and miracloth to obtain a S100 HeLa cytoplasmic extract.
The clarified extract is subjected to di erential precipitation with Poly Ethylene Gly-
col400 (PEG; number signifies the mean molecular weight of the PEG polymer). PEG400
is added at a concentration of 20 % (v/v) to the S100 HeLa cytoplasmic extract under
stirring at 4 ¶C and incubated for 20 minutes. Precipitated proteins are removed by cen-
trifugation at 30.000 x g for 30 minutes at 4 ¶C. The supernatant is then precipitated by
raising the concentration of PEG400 to 30 % (v/v) as described above. The precipitate
of this step, which contains human 20S proteasomes, is recovered by centrifugation at
30.000 x g for 30 minutes at 4 ¶C and resuspended in purification bu er containing 2 %
(w/v) sucrose, 10 mM DTT and 0.01 % (w/v) Lauryl Maltose Neopentyl Glycol (LMNG)
in an orbital shaker at 18 ¶C.
The resuspended material is loaded on 10-30 % (w/v) sucrose gradients in purification
bu er containing 5 mM DTT, which are centrifuged at 270.000 x g for 16 hours at 4 ¶C.
Gradients were harvested in 400 µl fractions using Äkta Prime. SDS-PAGE119 was uti-
lized to identify fractions containing 20S proteasomes. Selected fractions were pooled and
precipitated by the addition of 40 % (v/v) PEG400. After centrifugation (30.000 x g, 20
minutes), the supernatant was removed and the precipitate was resuspended in Purifica-
tion bu er containing 5 % (w/v) sucrose, 10 mM DTT and 0.01 % (w/v) LMNG. The
resuspended material is loaded on linear 10-40 % (w/v) sucrose gradients in Purification
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bu er containing 5 mM DTT, which are centrifuged at 284.000 x g for 20 hours at 4 ¶C.
Fractions containing 20S proteasomes are yet again identified by SDS-PAGE, precipitated
and concentrated by the addition of 40 % PEG400 and resuspended in Purification bu er
containing 5 % (w/v) sucrose, 5 mM DTT and 0.01 % LMNG, yielding the finally purified
protein preparation at 13 mg/ml.
Protein concentrations were determined by the Bradford assay (BioRad, Munich, Ger-
many) using BSA as a standard. This procedure reproducibly yields 20 mg purified human
20S proteasomes, starting from 300 ml S100 HeLa cytoplasmic extract at a concentration
of 10 mg/ml. The entire purification procedure is concluded within 48 hours yielding
crystallization grade protein.
The purification description is according to Schrader at al., 2016120.
2.2.1.2 Purification of 26/30S Proteasomes from HeLa Cells
Purification of human 26/30S proteasomes was performed according to the recently devel-
oped human 20S proteasome protocol, as described above. S30 HeLa cytoplasmic extract
is prepared by hypotonic lysis118, centrifuged at 30.000 x g for 30 minutes at 4 ¶C, flash
frozen in liquid nitrogen and stored at -80 ¶C.
The S30 extract was thawn in a water bath at 37 ¶C, supplemented with purification
bu er to 1x from a 10x stock, sucrose powder to 20 % (w/v), Octyl Glucose Neopentyl
Glycol (OGNG; from a 10 % (w/v) stock solution in water) to 0.1 % (w/v), Iodoac-
etamide to 10 mM, N-Ethylmaleimide to 10 mM, Benzamidine Chloride to 10 mM and
ATP to 7.5 mM. The extract was incubated at room temperature on a magnetic stirrer
for 30 minutes, followed by an addition of Dithiothreitol (DTT) powder to 50 mM and a
second incubation at room temperature for 30 minutes. The S100 extract was prepared
by centrifugation at 100.000 x g for 2 hours at 4 ¶C and the supernatant was filtered
through 3 layers each of cheese cloth and miracloth.
The S100 extract was processed by two subsequent rounds of precipitation with PEG400.
First, PEG400 was added to a concentration of 23 % (v/v) to the S100 extract at 18 ¶C
on a magnetic stirrer and incubated for 30 minutes. Second, the supernatant was precip-
itated by raising the concentration of PEG400 to 30 % (v/v) as described before. The
precipitate contains the human 26S/30S proteasomes and was resuspended with purifi-
cation bu er supplemented with 7.5 mM ATP, 5 mM DTT and 0.01 % (w/v) Lauryl
Maltose Neopentyl Glycol (LMNG) in an orbital shaker at 18 ¶C. The resuspended mate-
rial was incubated with an ATP regeneration system (10 mM Sodium Creatine phosphate,
5 µg/mL Creatine kinase) at 30 ¶C for 30 minutes.
The sample was loaded on 20 % / 50 % 2-step sucrose cushions in purification bu er
containing 7.5 mM ATP and 5 mM DTT. The cushions were centrifuged at 260.000 x g
for 14 hours at 4 ¶C, harvested in 500 µl fractions with Äkta PrimeTM (GE Healthcare ,
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Munich, Germany) and analyzed by SDS-PAGE to identify fractions containing 26S and
30S proteasomes. Fractions were pooled and precipitated by the addition of 40 % (v/v)
PEG400 for 30 minutes and after centrifugation (30.000 x g, 30 minutes) the precipitate
was resuspended in purification bu er containing 5 % sucrose, 7.5 mM ATP, 5 mM DTT
and 0.01 % (w/v) LMNG. The proteasomes were treated with Oprozomib at a concen-
tration of 0.5 mM at 25 ¶C for 30 minutes. Proteasomes were loaded on linear 10-40 %
(w/v) sucrose gradients in purification bu er containing 7.5 mM ATP, 5 mM DTT, which
were centrifuged at 220.000 x g for 16 hours at 4 ¶C. 400 µl fractions were analyzed by
SDS-PAGE, selected proteasome fractions were precipitated by the addition of 40 % (v/v)
PEG400 and resuspended in purification bu er containing 7.5 % (w/v) sucrose, 7.5 mM
ATP, 5 mM DTT and 0.01 % (w/v) LMNG.
As a final step, proteasomes were fractionated on linear 10-45 % (w/v) sucrose gradients
in purification bu er containing 7.5 mM ATP, 5 mM DTT, which were centrifuged at
260.000 x g for 16 hours at 4 ¶C. Fractions containing 26/30S proteasomes were yet again
identified by SDS-PAGE, precipitated by the addition of 40 % (v/v) PEG400 and resus-
pended in 2x purification bu er containing 15 % (w/v) sucrose, 15 mM ATP, 10 mM DTT
and 0.02 % (w/v) LMNG yielding the final purified protein preparation at 30 mg/ml.
Protein concentrations were determined by the Bradford assay (BioRad, Munich, Ger-
many) using BSA as a standard.
This purification procedure reproducibly yields 45 mg purified human 26/30S protea-
somes, starting from 800 ml S100 HeLa cytoplasmic extract at a concentration of 10 mg/ml.
2.2.2 Enzyme Kinetics
To determine the chymotryptic-like activity of the b5 catalytic active site of the human
20S proteasome, kinetic measurements were performed using a FluoroMax-4 fluorescence
spectrophotometer. Succinyl-Leucine-Leucine-Valine-Tyrosine-7-amido-4-methylcoumarin
(Suc-LLVY-AMC) was utilized as substrate. Enzyme kinetics were determined by mea-
suring the fluorescence emission of the hydrolyzed substrate at 460 nm (lex = 380 nM)
at a constant temperature of 37 ¶C.
The Suc-LLVY-AMC conversion was characterized using 50 nM human 20S proteasomes.
The proteasomes were pre-incubated in reaction bu er at 37 ¶C for 3 minutes. The re-
action was started by adding the substrate and the fluorescence signal was measured
continuously.
When analyzing the first-order rate constant of inhibition, the reaction mixture contain-
ing the reaction bu er, 150 µM Substrate and the respective inhibitor was pre-incubated.
The following inhibitor concentration were used: 50 µm Oprozomib, 50 µm Dihydroepone-
mycin, 15 µm Z-LLY-Ketoaldehyde. The reaction was started by the addition of human
2.2 Methods 37
20S proteasomes at a final concentration of 50 nM. Suc-LLVY-AMC and the inhibitors
were dissolved in DMSO and stored at -80 ¶C until usage. Data analysis was carried out
with OriginPro 9.1 (Origin Lab) and KaleidaGraph 4.03 (Synergy Software). To analyze
the chymotryptic-like catalytic activity and catalytic activation of the 20S proteasome
the following equation was used:
F (t) = F0 +  Fss · t ≠
( Fss ≠  F0)
kact
· (1 ≠ exp(≠kact · t)). (2.1)
where F0 denotes the fluorescence at time t = 0 and  Fss the increase in fluorescence
(activity) in steady state after activation.  F0 denotes the increase in fluorescence (activ-
ity) at time t = 0 prior to activation. kact denotes the first-order activation rate constant.
The first-order inactivation rate constants were determined by using the equation with
two exponential terms (Z-LLY-Ketoaldehyde) or two exponential terms and a linear term
for the epoxyketone inhibitors Oprozomib and Dihydroeponemycin. The first term makes
up the catalytic activation, whereas the second exponential term accounts for the cat-
alytic inactivation by inhibition. The linear term signifies the residual activity of the
proteasome after inactivation by epoxyketone inhibitors.
Data analysis was performed by Prof. Dr. Kai Tittmann, University Göttingen. The
method description is according to Schrader at al., 2016120.
2.2.3 Electronic Structure Calculations
Cluster calculations were carried out on selected model systems, considering the Dihy-
droeponemycin, Oprozomib and Z-LLY-Ketoaldehyde inhibitors. The starting structures
were based on the crystallographic data. All stationary points and constrained optimiza-
tions were carried out at the B3LYP-D3(BJ)/def2-SVP level of theory121,122,123,124, which
include dispersion corrections as suggested by Grimme, with a Becke-Johnson type damp-
ing125. The nature of the stationary points was confirmed by frequency calculations. The
reaction energy profiles are provided at the level of theory used for the optimizations
(B3LYP-D3/def2-SVP).
Free-energy corrections were computed from frequency analysis under the rigid-rotor har-
monic approximation of the latter structures. The electronic energy was determined at the
B3LYP-D3/def2-TZVP level of theory, under the COSMO continuum solvation model126.
Diethyl ether was employed as the solvent (e=4.3), which is commonly chosen to model
protein-like environments127. All free-energy values reported correspond to the sum of the
latter electronic energies and the thermodynamic corrections computed with the smaller
def2-SVP basis set. All calculations were carried out with the Orca 3.0.3 program pack-
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age128.
Cluster quantum chemical calculations were performed by Prof. Dr. Ricardo Mata, Uni-
versity Göttingen. The method description is according to Schrader at al., 2016120.
2.2.4 Crystallization Methods
2.2.4.1 Preparation of Protein Crystals
The basis for all protein crystallizations experiments is formed by the phenomenon that a
protein will stay in solution only upto a certain concentration, depending on its solubility
limit. Crystallization requires bringing the macromolecule to a supersaturation state.
Introducing the sample to a precipitation agent can promote the nucleation of protein
crystals in the solution.
The two main techniques to obtain crystals are vapor di usion and batch crystallization.
Vapor di usion is carried out in a hanging or sitting drop set up: A drop containing a
mixture of protein and precipitant is sealed in an environment of pure precipitant (Figure
2.1, A). Over time, dehydration of the protein drop takes place until an equilibrium
between drop and precipitant is formed. During the vapour di usion method, a protein
solution will start to concentrate from an undersaturated state to a supersaturated state.
If crystals are formed the concentration of the free protein in the drop will decrease and
crystals grow until the concentration of protein drops below to, or below the solubility
line (Figure 2.1, B). The vapor di usion techniques are easily adjustable by increase or
decrease of the starting protein concentration or by the ratio of protein to precipitant or
even by ratio of protein-precipitant mixture to the precipitant reservoir.
In the batch approach, the protein is mixed with a defined amount of the precipitant. To
prevent the drop from drying out, the procedure is performed under a para n/mineral
oil film, as shown in Figure 2.1, A. If the concentration of the precipitant is chosen in
such a way that the solution is in the metastable zone, a successful crystallization might
occur (Figure 2.1, B).
For the human 20S proteasome, crystallization attempts were carried out by the vapor
di usion method. With a vast number of possible crystallization conditions it took time
until di erent precipitant solutions and e ects of pH, temperature and additives were
analyzed and a final crystallization condition was found. The new crystal form of the
human 20S proteasome was obtained using the precipitant PEG3350 in combination
with the bu er substance BisTris at pH 6.5 and the salt additive MgCl2 (Crystallization
bu er).
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Figure 2.1: Crystallization techniques and the crystallization phase diagram. (A) Schematic
representation of vapor di usion techniques hanging and sitting drop and batch crystallization technique.
(B) Schematic representation of a two-dimensional phase diagram, illustrating the change of protein
concentration against precipitating agent concentration. Two areas are separated by the solubility line: the
undersaturated and the supersaturated state of a proteins solution. The supersaturated area comprises
the metastable and the precipitation zones, whereby crystals will eventually appear in the metastable
phase and no crystals are formed in the precipitation zone. Modified from Bernhard Rupp129.
2.2.4.2 Postcrystallization Treatment
To improve the di raction quality of macromolecular complexes it is almost always re-
quired to perform a postcrystallization treatment after crystals are obtained. Initial crys-
tals are often of poor quality and unsuitable for X-ray studies. Postcrystallization is a
method that provides the possibility to increase the di raction quality of crystals. For the
human 20S proteasomes one crucial step in crystal preparation is the dehydration, result-
ing in a controlled reduction of solvent molecules in the crystal and decrease of volume
of the crystal by altering the crystal packing. These rearrangements promote new crystal
contacts and thereby result in better di racting crystals. Dehydration is performed by an
increase or an introduction of precipitant: here PEG3350 and MPD.
40 2 | Materials and Methods
2.2.5 X-ray Analysis Methods
2.2.5.1 Crystal Mounting and Di raction Data Collection
After post crystallization treatments the human 20S proteasome crystals are ready for
harvest. Crystals are harvested in Litholoops mounted on a standard 18 mm stainless
steel pin and plunged in liquid nitrogen or directly transfered to a nitrogen gas stream at
100 K. X-ray di raction data was collected under cryogenic conditions at 100 K. Initial
crystal screening and data collections were performed at beamline ID23-I, ESRF, Greno-
ble, France using the PILATUS 6M detector. The high-resolution di raction datasets
were collected at the P14 beamline of the Petra III storage ring, EMBL, Hamburg, using
the MD3 di ractometer with the spindle axis mounted in a vertical and downward con-
figuration and the PILATUS 6M detector.
At the P14 beamline, a smooth "top-hat" X-ray beam profile with a total photon flux
of up to 2x 1013 ph/ sec was created by the installation of focusing Compound Refrac-
tive Lenses 20.6 m upstream of the sample position and slits 0.3 m upstream. To get
beam-sizes matching the crystal sizes the slit opening was adjusted (150 x 200 µm2 in lin-
ear dimensions). Exposing the whole crystal provided by far the best resulting datasets.
Standard setups with small X-ray beams or helical data collection only resulted in 2.3 Å
maximal resolution.
Crystals were exposed 40 ms per image with a gamma-slicing of 0.05 - 0.1 in a total
rotation range of 180¶ - 360¶ at 50% attenuation. The collected datasets were rapidly
scaled and integrated with the XDS program package.
2.2.5.2 Structure Determination
For model building the initial phases were determined by molecular replacement using the
murine 20S structure (PDB ID: 3UNE). Model building and optimization was performed
using COOT111. Subsequent refinement was performed using the program REFMAC5
in the CCP4 package130. Final graphic representations of details in the crystal struc-
ture were completed using the programs PYMOL and COOT. For modeling the bound
inhibitors, complete stereo-chemical descriptions of double- or single-covalent link attach-
ments were created using the program JLigand114 and applied in real-space fitting with
COOT followed by a refinement with REFMAC5.
2.2.5.3 Identification of Ions
The identification of many ions in the native 20S structure was validated by anomalous
di erence Fourier maps. For ligands in question, soaking experiments with anomalous
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scatterers were performed: Cl- ions were identified by their anomalous Fourier di erences
at 6.5 keV and by exchange against Br- ions and measurements at the bromide K- absorp-
tion edge (13.47 keV). Mg2+ ions were identified by exchange through soaking crystals
with Mn2+ ions and measurements at the manganese absorption edge (6.5 keV). K+ ions
were identified by their residual anomalous scattering at 6.5 keV, non-exchangeability by
either Br- or Mn2+ and by measuring the coordination distances to neighboring residues
within the structure.
2.2.6 Sample Preparation for Electron Microscopy
2.2.6.1 GraFix
The purified human 26S proteasomes were prepared for EM analysis by a fixation proto-
col: First, the sample was fixated in batch, using 2 mM of the crosslinking agent BS3 for
30 minutes at 4 ¶C. The BS3-fixed protein sample was then loaded onto 10-30 % (w/v)
GraFix gradient in which the complexes are centrifuged into an increasing concentration
of the fixation reagent glutaraldehyde. The gradients contained 0-0.05 % (w/v) glutaralde-
hyde and were centrifuged for 16 hours at 114000 x g. The human 26/30S proteasomes
sediment to 2/3 of the gradient and the exact fraction is determined by fractionation and
dotblot analysis. Dotblot is performed by pipetting 2 µl of each sample fraction onto a
nitrocellulose membrane and subsequent staining with amido black solution. After frac-
tionation, the sample is immediately quenched by adding 20 mM of sodium aspartate
(pH 6.5).
2.2.6.2 Negative Staining
The fractions containing the 26/30S proteasomes were analyzed by negative stain elec-
tron microscopy. A 2 % (w/v) uranyl formate solution was prepared freshly in double
distilled water. In-house prepared carbon film was floated on the protein solution for up
to 1 minute, depending on the protein concentration. The foil with the attached protein
complexes was picked up by a holey carrier carbon film on a copper grid. Excess liquid
was removed by gentle blotting of the grid with a filter paper. The grid containing foil
and particles was then transfered onto the staining solution for 1 minute. The excess
staining solution was blotted with a filter paper and the grid was allowed to air dry at
room temperature for at least 10 minutes.
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2.2.6.3 Vitrification
After determination of the sample’s quality by negative stain electron microscopy the
sample was prepared for subsequent vitrification for cryo-EM analysis. For a successful
cryo grid preparation the sucrose had to be removed from the protein sample. Almost all
sucrose is removed by bu er exchange on Zeba Spin desalting columns and the particles
were absorbed by continuous foil, as described before. The foil was picked up by a quan-
tifoil grid containing a thick carbon film. Thereafter, the grid is loaded into the Vitrobot
or Leica EM GP apparatus. 4 µl of water is loaded to one side of the grid before blotting
at 4 ¶C at 100-75 % humidity. The grid was then plunge-frozen into liquid ethane and
the thin water film with the particles on the grid was vitrified. Grids were stored in liquid
nitrogen until usage.
2.2.7 Imaging of Electron Microscopic Data
Negative stain electron microscopic analysis was performed on a CM200 FEG microscope.
Images were taken at 1 µm defocus on a twice binned CCD camera at a magnification
of 88000 x. The corresponding pixel size is 2.5 Å/pixel. High-resolution cryogenic elec-
tron microscopy was performed on a Titan Krios TEM microscope equipped with a
CS-corrector. 17 image frames were recorded on a direct electron detector (Falcon2) with
a dosage of 50 electrons per Å2 with a pixel size of 1.27 Å.
2.2.8 Image Processing
Image processing of the human 26S proteasome was performed by Dr. David Haselbach,
Structural Dynamics Department at the Max Planck Institute for Biophysical Chemistry,
Göttingen.
2.2.8.1 Micrograph Analysis and Particle Picking
Individual image frames were aligned and weighted according to electron dose to reduce
the e ects of drift and charging using the software unblur131. The Contrast Transfer
Function (CTF) was determined on averaged micrographs with Gctf112. Particles were
selected with the software Gautomatch132 and individual particle coordinates were refined
by alignment against a projected model of the 26S proteasome. Particles were cropped in
a window 1.5 times in diameter.
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2.2.8.2 2D Processing
For 2D analysis, particles were down-sampled to a pixel size of 4 to 8 Å/pixel as well as
filtered and normalized. Several image sorting steps to remove contaminations, blurred
images or broken particles were performed: First, power spectra for each particle were
calculated and classified using a hierarchical cluster scheme. The resulting class averages
were visually inspected for the Thon ring quality. Strongly charged and/or blurred classes
were discarded. Second, iterative rounds of multi-reference alignment and 2D classification
were performed. Particles sampled into classes which do not show intact proteasome
particles were discarded.
2.2.8.3 Initial Model Building
After particle sorting, the best class averages were chosen and an initial 3D model was
generated with the program simple PRIME116. This independent approach produces 3D
models based on an iterative projection-matching approach without the need of an initial
model.
2.2.8.4 Conformational Sorting
The resulting 3D model was used as the initial reference for 3D classification, using
the program RELION115. Here, all particles were classified according to the two main
conformational states (non-rotated and rotated). The flexible protein Rpn1 was masked
out because it interferes with the alignment.
2.2.8.5 Refinement and Resolution Determination
The particles belonging to the non-rotated state were refined using the "auto-refine" rou-
tine in RELION. Further hierarchical sorting was performed in RELION to sort particles
regarding to various regulatory particle conformations: A series of 3D classification steps
without alignment with decreasing mask size was performed. After 4 refinement steps,
98000 particles contributed to the final 26S proteasome model (details in Results section).
A local resolution map was estimated in ResMap133, calculating local Fourier Shell Cor-
relation (FSC) values in a sphere with a diameter of 13 voxels, scanning the entire 3D
model.
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2.2.8.6 Model Building
For the 20S particle, the crystal structure of the Oprozomib-inhibited human 20S protea-
some was used as initial atomic coordinate model (PDB entry: 5LEY)120. Models of each
regulatory particle protein were generated with Robetta134,135 and docked as rigid bodies
into the EM density map with UCSF Chimera117. Nucleotides were placed by fitting the
crystal structure of PAN (PDB entry: 3H4M)136 into the density.
Secondary structure prediction for regions that were modeled partly or completely de
novo were obtained using the server psipred137. The initial rigid body refinement was
performed using real space refinement in Phenix138 and modeling was carried out manu-
ally in COOT.
Secondary structure restraints were generated using phenix.ksdssp and all secondary struc-
ture restraints were visually inspected and required restraints were added manually. The
real space refinement was performed over several iterative rounds.
2.2.8.7 Validation
For datasets which yield two or more main conformations, the structural model is val-
idated by a cross reference test. Here, the particles corresponding to one conformation
were refined on a model with the alternative conformation. The final 3D reconstruction
relaxed back to the originating model and the sorting was considered as valid.
2.2.9 Visualization of the Conformational Space of the Human
26S Proteasome
If not stated di erently, particles with and without Oprozomib bound to the proteasome
were treated as separate subsets. All particles of one subset were refined against the ini-
tial 26S proteasome map using RELION to gain alignment parameters. This reduces the
subsequent calculations in the classification step. The resulting aligned images were ran-
domly split in subsets of 100,000 particles and a RELION 3D-classification139, yielding
40 classes per subset, was performed, without aligning the particles again. Each resulting
3D class was further refined with the assigned particles using RELION.
In total, 346 classes were obtained. To further analyze the motions between the classes
we used principle component analysis (PCA). The result of a PCA are eigenvectors that
describe the largest covariance within the dataset. In aligned 3D volumes of the same
molecule, the largest covariance are primarily movements within the molecule140. The
eigenvectors can be used as conformational coordinates141. Before applying PCA, the re-
fined 3D-classes were aligned in UCSF Chimera against a model of the most rigid part of
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the 26S complex; the 20S proteasome subcomplex. This is necessary to avoid calculating
eigenvectors which describe shifts and rotations of the 3D-classes among themselves. 3D
classes from datasets with and without Oprozomib were combined and normalized, and
subsequently eigenvectors were calculated using PCA. Hence, the eigenvectors describe
the movements found in both datasets and allow us to compare the results. One can then
describe the conformers Xi on a coordinate en (the eigenvector describing movement n) by:
Xi = an,ien + X (2.2)
where X is the average volume, en is a specific eigenvector and an,i is a linear factor.
In other words, en is a conformational coordinate and an,i places the conformer Xi at
its specific place on this conformational coordinate. The addition of the mean volume
results from the definition of PCA. Eigenvectors and their corresponding trajectories can
be sorted according to their contribution to the overall mobility.
The movements described by the conformational coordinates might however be composed
out of several primitive motions of the molecule. Therefore, one cannot assign a single
measure (e.g. rotation angle, translation movement) to all of these movements. The fol-
lowing movements were found and are listed descending in the value of the covariance:
Table 2.5: Eigenvectors and the corresponding conformational changes.
Eigenvector Description
1 Rotation of the Lid and translation of the ATPase domain
2 Resolution di erences
3 Conformational stabilization of Rpn9
4 Conformational stabilization of Rpn5, 10 and 12; Movement of Rpn1
5 Motion of Rpn1; Conformational stabilization of Rpn9, 10
6 Translation of Rpn2, 3, 7, 12
7 Stretching of the Lid; Movement of the central helical bundle
(Rpn3, 6, 8, 11); Movement of ATPase domain
8 Rise of the ATPase (including Rpn1); Sinking of Rpn2 and 8
9 Rotation of Rpn1
10 Small movements
To understand the motion described by the eigenvectors, video trajectories where inter-
polated using equation 2.2 and subsequent morphing in UCSF Chimera. Then, for each
3D class the linear factors with respect to each eigenvector were determined. By placing
the di erent conformers on the reaction coordinates energetic conclusions can be drawn.
Knowing the number of particles assigned to each class, we can calculate their free energy
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di erences   G by the BOLZMANN Factor:




where T is the absolute temperature, pi is the number of particles in state i and p0 is the
number of particles in the most populated state142. The number of particles belonging
to each 3D was counted from the respective data output files from RELION115. Free
energy di erences were calculated using equation 2.3 as multiples of kBT . From equa-
tion 2.3 it becomes clear that regions with high energies have a lower number of single
particles belonging to them. To visualize the energy landscape with and without Opro-
zomib, combinations of two eigenvectors were used as the axis of a new three-dimensional
coordinate system. The 3D classes were placed as data points in these landscapes with
the dimensions being the respective linear factors an,i and am,i, and the di erence in free
energy   G. We could then describe energy landscapes in which the molecule moves by
interpolating between these discrete states.
To account for false-positives, for example 3Ds which are classified in two separate classes
but do only di er slightly, we applied a final binning of close data points. Therefore, all
data points within a given distance were averaged. This distance was set to the half-
width of the peak around one linear factor. These landscapes have important limitations.
In contrast to for example Molecular Dynamics simulations, the 3D volumes yielded from
single particle analysis sample the conformational space discrete and sparse. Hence, large
areas in the landscapes, especially those of high energy, are highly interpolated. This is
also apparent in the fact that the very low sampled areas close to unfolding and complex
decomposition are not accessible to this method. However, this method o ers an oppor-
tunity to quantify the results of 3D classifications and, as in our specific case, allows us
to learn about the influence of small molecule binding on the functional conformational
landscape of a macromolecular machine.
This method was developed by Dr. David Haselbach and Felix Lambrecht in the Structural




3.1 Native Human 20S Proteasomes and in Complex
with Inhibitors
The structure determination of macromolecular complexes by X-ray crystallography de-
pends on the availability of crystals that di ract to suitably high resolution. Crystal-
lization conditions are known for 20S proteasomes from various organisms, and crystal
structures up to a resolution of 2.4 Å were previously published16,23,25,143.
In this section, the outcome from novel purification strategies, new crystallization con-
ditions and post-crystallization procedures with the resulting high-resolution structures
of the native human 20S proteasome and its complexes with 20S inhibitors are pre-
sented.
3.1.1 Purification and Crystallization of the Human 20S Pro-
teasome
The starting point for the successful structure determination of human 20S proteasomes at
a significantly higher resolution is a novel concept of protein purification. For human 20S
proteasomes, a chromatography-free purification technique was established and optimized
(Figure 3.1, A for a schematic description of the procedure and Figure 3.1, B for a
representative SDS-PAGE of individual steps of the 20S proteasome purification).
The purification strategy is simple, rapid, and enables the purification of human 20S
proteasomes within 48 hours. The purification is chromatography-free and starts with
the treatment of cytosolic extract of HeLa cells. After centrifugation of the extract at
30000 x g for 30 minutes (S30 extract preparation), the supernatant is incubated with
2-Iodoacetamide and N-Ethylmaleimide for 30 minutes and centrifuged at 100000 x g
for 2 hours (S100 extract preparation). The resulting supernatant is then subjected to a
combination of di erential precipitation with the polymer PEG400 and sucrose gradient
centrifugation. Fractions containing 20S proteasomes are identified by SDS-PAGE after
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each purification step. This procedure reproducibly yields 20 mg purified human 20S
proteasomes, starting from 300 ml cytosolic HeLa extract at 10 mg/ml.
The resulting highly soluble and stable human 20S proteasomes have a specific activity of
13 nmol/mg-1/min-1 in the activation phase (pre-steady-state) and 60 nmol/mg-1/min-1
in the steady-state phase (Figure 3.1, C). This means that the human 20S proteasomes
purified by the chromatography-free purification method have a higher specific activity
by a factor of 10 than reported for previous 20S proteasome preparations22.
Figure 3.1: The high-throughput purification procedure. (A) Schematic representation of the
entire high-throughput pipeline to purify human 20S proteasomes from HeLa cytoplasm. (B) SDS-
polyacrylamide gel electrophoresis analysis of distinct steps of the purification procedure. Samples of
the S30 (lane 2) and S100 (lane3) extract, the 20-30 % (v/v) PEG400 cut (lane 4), the pool of the first
(lane 5) and second (lane 6) sucrose gradient centrifugation, the purified 20S proteasome sample (lane
7) and a marker as reference (lane 1) are depicted. (C) Activity of the human 20S proteasome from
the chromatography-free purification. The increase in fluorescence signal of AMC release by proteolytic
cleavage is plotted against time. Figure adapted from Schrader et al., 2016120.
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3.1.1.1 Preparation of Human 20S Proteasome Crystals
The freshly purified protein is diluted with purification bu er to a concentration of
7.5 mg/ml and crystallized by mixing 0.5 µl protein and 0.5 µl crystallization bu er
in Chryschem sitting drop vapor di usion plates over a 500 µl reservoir of crystallization
bu er. Within 4 hours, nucleation takes place and the first small crystals are detectable.
To depict the time course of human 20S crystallization, a time-lapse experiment was per-
formed and the results are shown in Figure 3.2. Within 24 hours the crystal grows to its
full size, 150 x 150 x 200 µm3.
Figure 3.2: Time-lapse experiment of human 20S crystallogenesis. Timepoints are 0, 2, 4, 6, 8,
and 20 hours. Nucleation takes place after 4 hours and crystals grow within 24 hours to their full size.
Figure adapted from Schrader et al., 2016120.
3.1.1.2 Postcrystallization Treatments
To gain a high reproducibility in crystal di raction to 1.8-2.2 Å resolution, the human
20S proteasome crystals need to be stabilized and dehydrated in a controlled manner.
Extensive time and e ort was spend to find the optimal procedure.
Finally, three steps seem to be critical and necessary for highly reproducible crystal
di raction: 1) Crystals initially grown at 18 ¶C are transfered to incubators where the
temperature is decreased to 4 ¶C within 24 hours. When at 4 ¶C the crystals are carefully
transported into the 4 ¶C room. All postcrystallization treatments take place at 4 ¶C.
2) The seals are removed and 1 µl of the reservoir solution is added to the 1 µl drop.
Subsequently, 2 µl of the crystal stabilization bu er is added to the drop and the reservoir
solution is exchanged against the stabilization bu er. The wells are re-sealed and equili-
bration against the new reservoir by vapor-di usion takes place in excess of 8 hours at
4 ¶C. 3) If needed, ligands (e.g. proteasome inhibitors) are soaked into the crystal when
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analyzing the inhibitor-proteasome complexes. Inhibitors are soaked into the crystals by
adding 4 µl of dehydration bu er, which additionally contains 5 mM of the proteasome
inhibitor to gain a final concentration of 2.5 mM. The wells are re-sealed and equilibration
against the new reservoir by vapor-di usion takes place in excess of 12 hours at 4 ¶C.
The full post crystallization protocol is concluded within 30 hours.
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3.1.2 Native Crystal Structure of the Human 20S Proteasome
In this thesis, a high resolution structure of the native 20S proteasome at an unprece-
dented resolution of 1.8 Å is presented. A di raction pattern of the stabilized and dehy-
drated human 20S proteasome crystals measured at beamline P14 in Hamburg is shown
in Figure 3.3, A.
The determination of the native structure at 1.8 Å provides better insights into the archi-
tecture of the entire particle and its active sites. The obtained structures display excellent
stereochemistry with values for Rwork= 18 % and Rfree= 21 % (Table 3.1) and the final
crystallographic maps reveales clear electron densities for all 6724 residues and allows the
identification of several ligands present in bu ers used for purification and crystalliza-
tion (Figure 3.3, B). The identity of many ions was validated by anomalous di erence
Fourier maps. In the final structure, 58 chloride, 15 magnesium and 6 potassium ions, in
addition to several PEG molecules and more than 3500 localized water molecules were
assigned.
Table 3.1: Data collection and refinement statistics of the native 20S crystals. Values in
parenthesis denote values for the highest resolution shell. Number of unique reflections used in refinement
are shown.
Tag Native Native
PDB ID 5LE5 5LEX
Divalent salt MgCl2 Mg(OAc)2
Space group P212121
Unit cell
a (Å) 113.4 113.9
b (Å) 202.8 203.1
c (Å) 316.0 316.0
Data collection
Wavelength (Å) 0.976
Resolution range 107-1.80 50-2.20
(Å) (1.90-1.80) (2.28-2.20)
No. of reflections 8923661 2519654
No. of unique 633728 366080
reflections
Completeness (%) 99.9 (99.7) 99.2 (98.1)
<I/SigI > 18.5 (0.91) 13.0 (0.9)
CC1/2 1.00(0.32) 1.00(0.36)







R.m.s.d. bond 0.018 0.015
length (Å)
R.m.s.d. bond 1.92 1.72
angle (Å)
Ramachandran
% most favored/ 95.88/3.06 95.60/3.29
/favored
In Figure 3.4 the active sites of all three catalytic sites of the 20S proteasome and the
identified ligands are shown. At 1.8 Å resolution, a number of di erences with respect to
the previous published structures become visible. Particularly, a chloride ion is present
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Figure 3.3: Di raction pattern and structural details at 1.8 Å resolution. (A) A typical di rac-
tion pattern of stabilized and dehydrated human 20S proteasome crystals measured by the oscillation
method at beamline P14, EMBL Hamburg. Beam size matched crystal size, exposure time was 40 ms and
the oscillation range 0.05¶. The di raction limit is 1.8 Å. (B) The electron density gives insight into the
quality of the high resolution structure at 1.8 Å resolution. Shown is a potassium (magenta)-magnesium
(light green) double ion site, stabilizing the b6-b2 interface. Protein main chains and side chains belonging
to the b6 subunit are labeled in black. Protein main chains and side chains belonging to the b2 subunit
are labeled in green. The sA-weighted electron density map is shown contoured at 1.5 s. Figure adapted
from Schrader et al., 2016120.
in all three sites, which was previously described as a catalytic water (NUK). Soaking
experiments, where crystals grown in MgCl2 were soaked with Mg(OAc)2, replace the
Mg2+ ion against a water molecule. Additionally, up to three localized water molecules
(H2O-1, -2, -3) are present in the active sites. These findings imply a new interpretation
of the inhibition mechanism: A water in the NUK position might act as a proton shuttle.
The putative role of this water was analyzed at a later point (see below).
Figure 3.4: Close-up view of all three catalytic sites of the high resolution 20S structure. (A)
b1-subunit caspase active site with Thr1, Thr2, Ile3, four H2O molecules and a NUK chloride (green). (B)
b2-subunit tryptic active site is shown in the same orientation as in (A). Shown are two H2O molecules,
as well as the NUK chloride. (C) b5-subunit chymotryptic active site depicted as in (A) and (B), shown
are three H2O molecules and the NUK chloride. The 2mFo-DFc electron density map is shown contoured
at 1.5 s. Figure adapted from Schrader et al., 2016120.
3.1 Native Human 20S Proteasomes and in Complex with Inhibitors 53
3.1.3 Crystal Structures of Seven Inhibitor Complexes of the
Human 20S Proteasome
In addition to the native structures, six structures of the human 20S proteasome in com-
plex with inhibitors at resolutions between 1.9 and 2.4 Å were elucidated. Four of these
complexes describe proteasomes with inhibitors which are in clinical trials for the treat-
ment of cancer. Binding of these inhibitors to the human 20S proteasome was structurally
uncharacterized prior to this work. Oprozomib, Dihydroeponemycin, Ixazomib, and De-
lanzomib were chosen. They belong to three di erent inhibitor classes: a’,b’-Epoxyketone,
a-Ketoaldehyde and Boronic acid. All inhibitors used in this experiments are described to
have a specificity for the b5 subunit and in all further steps the analysis of the inhibitors
is restricted to this active site. In Table 3.2 the most important data collection details
and refinement statistics are depicted.
Table 3.2: Crystallographic data collection and refinement statistics of inhibitor-20S com-
plexes. Colors indicate the di erence in inhibitor classes. Statistics for epoxyketone inhibitors (blue),
ketoaldehyde inhibitors (violet) and boronic acid inhibitors (green) are listed, respectively the PDB entry
ID. Values in parenthesis denote values for the highest resolution shell. Number of unique reflections used
in refinement is shown.
Inhibitor Class Epoxyketone Ketoaldehyde Boronic acid 




Bortezomib Ixazomib Delanzomib 
PDB ID 5LEY 5LEZ 5LF0 5LF1 5LF6 5LF3 5LF7 5LF4 
         
Divalent salt MgCl2 Mg(OAc)2 MgCl2 MgCl2 MgCl2 MgCl2 MgCl2 MgCl2 
         





































Data collection         



















No. of reflections 2653718 2510786 2519995 4381423 2792074 2017022 3047303 4210019 
No. of unique 
reflections 
526170 351230 262073 464668 403247 393306 459417 462522 
Completeness (%) 97.5 (99.4)  99.3 (94.3) 99.9 (99.6) 99.8 (98.3) 96.4 (72.3) 98.7 (89.1) 99.8 (99.6) 99.1 (90.0) 
<I/SigI> 15.3 (0.83) 15.2 (1.1) 13.1 (0.83) 12.2 (1.0) 12.9 (0.6) 12.4 (0.9) 14.6 (1.0) 11.3 (1.0) 
CC1/2 1.00 (0.24) 1.00 (0.40) 1.00 (0.28) 1.00 (0.39) 0.99 (0.22) 1.00 (0.26) 1.00 (0.29) 0.99 (0.34) 
Rp.i.m. 0.041 (1.03) 0.036 (0.81) 0.060 (1.06) 0.038 (0.69) 0.043 (1.0) 0.052 (0.87) 0.041(1.1) 0.045 (0.81) 
         
Refinement         
Rwork 0.189 0.181 0.168 0.175 0.185 0.183 0.182 0.184 
Rfree 0.224 0.222 0.227 0.209 0.226 0.225 0.215 0.217 





















0.016 0.015 0.018 
 
0.014 0.013 0.014 0.013 0.012 
R.m.s.d. bond 
angles (Å) 
1.80 1.75 1.89 1.71 1.65 1.72 1.68 1.642 
Ramachandran 


















The high-resolution human 20S proteasome structures in complex with inhibitors reveal
di erences to earlier published data. The most prominent di erences are visible in the
20S-Oprozomib structure at 1.9 Å resolution. After refinement, the linkage of Oprozomib
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to the active site revealed a cyclic moiety. Unlike the previously predicted 1,4-morpholine
ring closure, the electron density map revealed a larger, 7-membered ring structure. This
ring-shaped structure could be modeled as a 1,4-oxazepane linkage, where the C6-methyl
group is oriented towards the the inner side of the ring (Figure 3.5). Additionally, all
three localized water molecules are displaced by the bound inhibitor and an epoxyketone
specific water molecule is hydrogen-bonded to the C6-OH and to Thr21 g-OH, referred
to as EK-H2O.
These findings suggest that the ring closure proceeds via a nucleophilic attack by the
N-terminal amine of the epoxide b carbon and not by the epoxide a carbon, as reported
for the 6-ring closure.
Figure 3.5: High-resolution human 20S proteasome in complex with Oprozomib. (A) The
b5 active site inhibited by Oprozomib at 1.9 Å. The omit map for the inhibitor, the cyclic linkage, and
bThr2 is contoured at 4 s. Depicted side chains are enumerated and the NUK chloride is shown as a green
dot. The inhibitor is covalently attached to Thr1 are depicted in ball-and-stick representation. Dashed
lines indicate hydrogen bonds at Æ 3.2 Å distance. (B) Close-up view of the 7-membered ring-closure,
along with the corresponding omit map contoured at 6 s. (C) Chemical structure of Oprozomib. Figure
adapted from Schrader et al., 2016120.
In the following, a multitude of control experiments to validate the 1,4-oxazepane ring
formation were carried out: (I) 20S proteasome crystals were grown as described be-
fore. After full growth, the crystals were soaked with Mg(OAc)2 prior to soaking with
the inhibitor Oprozomib. In the calculated electron density, an exchange of the chloride
molecule for an acetate molecule was detected, while the formation of a 1,4-oxazepane
linkage was not a ected. As seen in Figure 3.6 the electron density in the active site rep-
resents the larger 7-membered ring and an additional acetate molecule is present. This
acetate molecule forms hydrogen-bonds to each of the C6-OH and the C7-OH of the
1,4-oxazepane ring as well as a hydrogen bond to the amide of the main chain segment
Ser130. These findings show that the exchange of chloride for acetate does not a ect the
formation of a 7-membered, 1,4-oxazepane linkage.
(II) This experiment was performed to ensure that the formation of the 1,4-oxazepane
ring linkage is not a consequence of radiochemistry during X-ray data collection. First,
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Figure 3.6: Active site of Acetate and Oprozomib
soaked 20S crystals. Crystals soaked with Mg(OAc)2 be-
fore soaking with inhibitor, show the presence of an ac-
etate molecule in the active side together with the covalently
linked inhibitor. The close-up view shows the 7-ring struc-
ture together with the acetate which is hydrogen-bonded to
two oxygen atoms of the 1,4-oxazepane ring. Hydrogen bonds
are visualized as dashed lines. Figure adapted from Schrader
et al., 2016120.
a complete dataset at a low X-ray dose (0.7 MGy) was collected (Figure 3.7, A), then
the crystal was treated with a high dose (15 mGy) exposure followed by the collection of
a second dataset at 0.7 MGy exposure (Figure 3.7, B). The calculated electron density
maps revealed no obvious di erences and that the 7-ring is not a consequence of radiation
damage.
Figure 3.7: Low-dose experiment. Shown are the electron density maps of the ring linkage region
from a (A) low-dose and (B) a high-dose exposure. Both maps show electron density for the 1,4-oxazepane
7-membered ring and no obvious di erences are discernable. Figure adapted from Schrader et al., 2016120.
(III) Next, crystals were soaked with the natural product epoxyketone, Epoxomicin.
Di raction data to 2.4 Å were collected. The structure was calculated by refinement
of the integrated and scaled X-ray data against the present model of the native human
20S. The electron density maps in the human epoxyketone-20S proteasome crystal struc-
ture revealed density for the bigger 7-ring linkage formation. Modeling the cyclic molecule
visible in the inhibited state reveals that it represents the 1,4-oxazepane ring structure.
Figure 3.8 illustrates the b5 active site bound by Epoxomicin at 2.4 Å accompanied by
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an omit map for the inhibitor, covalent linkages, and the b5Thr2, as well as the chemical
structure of Epoxomicin.
Figure 3.8: Epoxomicin-human 20S proteasome co-crystal structure. (A) Shown is the b5
active site inhibited by Epoxomicin at 2.4 Å. The omit map is contoured at 4 s. Depicted side chains
are enumerated and the NUK chloride is shown as a green dot. Dashed lines indicate hydrogen bonds
at Æ 3.2 Å distance. (B) Close-up view of the 7-membered ring-closure, along with the corresponding
omit map contoured at 6 s. (C) Chemical structure of Epoxomicin. Figure adapted from Schrader et al.,
2016120.
(IV) A high-resolution structure of the human 20S proteasome bound by another nat-
ural epoxyketone product, Dihydroeponemycin, was determined. In contrast to the pre-
viously investigated epoxyketone inhibitors Oprozomib and Epoxomicin, Dihydroepone-
mycin shows a methanolic group at the a carbon (Figure 3.9, A and B). At a resolution
of 2 Å the di erence between an a carbon methyl group and a methanolic group should
further confirm the given ring-closure. If the binding would result in the formation of a
1,4-morpholine ring, then the calculated structure would reveal two methanolic groups
at the carbon 6 position. Instead, the electron density for the Dihydroeponemycin-20S
structure represents a 7-ring closure similar to the Epoxomicin and Oprozomib structures.
Here, one methanolic group at the C6 atom oriented to the inner side of the ring is visible
(Figure 3.9, C and D).
(V) Since the finding of a 7-ring closure in the inhibited 20S proteasome is described
for the first time, it was important to assure that the alternative 6-ring formation is
not present in the data and the 7-ring is not just one possible ring closure besides the
6-ring. This question lead to the next experiment, to investigate if the 6-ring formation
is an alternative ring-closure form. Therefore, a 6-ring model was refined against the
Oprozomib-20S X-ray data. The result, depicted in Figure 3.10, showed a poor quality
fit. It forces the structure to adapt the 6-ring formation, which leads to tremendous
distortions in the molecular geometry of the model: (i) the N4-carbon bonds are elongated
by 0.1-0.2 Å, (ii) the C5-alcohol bond is shortened by 0.1 Å, (iii) the bond-angle of the
C5-methylalcohol di ers by -20 degrees from the expected value, (iv) the van-der-Waals
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Figure 3.9: Validation of the ring closure in the 20S-Dihydroeponemycin crystal structure.
(A) Chemical structure of Oprozomib. (B) Chemical structure of Dihydroeponemycin. In (A) and (B)
the red oval highlights the reactive head group: the Oprozomib contains a methyl group and Dihydroe-
ponemycin a methanolic group in the a-position to the ketone. (C) Close-up view of the 7-membered
ring-closure upon Oprozomib inhibition, along with the corresponding omit map contoured at 6 s. (D)
Close-up view of the 7-membered ring-closure upon Dihydroeponemycin inhibition, along with the corre-
sponding omit map contoured at 6 s. The Dihydroeponemycin structure does not reveal electron density
consistent with the presence of two methanolic groups.
distance between the C5-methyl alcohol and two main chain oxygen atoms (R19, Y169) is
too short with 3 Å and would result in repulsion forces, and moreover, (v) strong negative
di erence density peaks in di erence maps contoured at 5 s levels at the C5 methanol
oxygen of the 1,4-morpholine ring model, as well as positive density peaks contoured at
4.5 s levels close to positions 4 and 5 of the 7-ring model remained after 6-ring refinement.
Adding it all up, the 6-ring formation cannot be considered as an alternative ring-closure
upon epoxyketone inhibitor binding.
Figure 3.10: Competitive refinement. The compet-
itive alignment of 1,4-morpholine versus 1,4-oxazepane
linkage reveals a poor fit and severe distortions can be
observed. Shown is an overlay of the active site inhib-
ited by a 7-ring linkage (yellow) and the attempted 6-ring
linkage (green). The strong negative di erence density is
visible at the C5 methanol atom in red, positive densi-
ties in green at positions 4 and 5. Figure adapted from
Schrader et al., 2016120.
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3.1.4 Structural Implications of the Six-ring Linkage
To investigate structural implications of a real six-ring linkage, a structure of the hu-
man 20S proteasome with the inhibitor Z-LLY Ketoaldehyde was determined and an-
alyzed at 2.1 Å resolution. Z-LLY-Ketoaldehyde belongs to the inhibitor class of the
a-ketoaldehydes, which possess only an electrophile in the a position. It is therefore only
capable of forming a 6-membered ring linkage.
The structure revealed that the ring-closure is without a doubt formed by six carbon
atoms (Figure 3.11). The electron density at the active site shows a clear density for
a hydroxyl group at the C5 position of the linkage, which indicates a formation of a
1,4-morpholine linkage. This is unlike previously published data where the ring closure
for a-ketoaldehydes was proposed to be a 6-membered heterocyclic, 5,6-dihydro-2H-1,4-
oxazine ring.
Considerable di erences become visible when comparing the coordination of the pre-
sented epoxyketone-inhibited structures forming the 7-ring linkage to the 6-ring forming
ketoaldehyde-inhibited structure. First, the NUK chloride molecule is absent and instead
a water molecule is present in a new position 1.2 Å away from the NUK chloride side.
This water molecule forms hydrogen bonds to the Ser130-amine and g-OH as well as
to N4 and C6-OH of the 1,4-morpholine ring. The C5-OH moiety, characteristic for the
1,4-morpholine ring closure, is stabilized by a dense hydrogen-bond network involving the
carbonyl atoms of Arg19 and Tyr169, the nitrogen of Lys33, and the active site H2O-3
(CAT).
These results indicate that the H2O-3 might play a role in both proteasomal catalysis of
peptide cleavage and in the cyclization step of the inhibition reaction.
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Figure 3.11: Ring-closure in the human 20S proteasome structure in complex with Z-LLY-
Ketoaldehyde. (A) Chemical structure of Z-LLY-Ketoaldehyde. The red circle highlights the reactive
head group with the electrophile in the a-position. (B) Close-up view of the 6-membered ring-closure,
along with the corresponding omit map contoured at 6 s. The arrow points to the C5 position where
a clear electron density for the hydroxyl group is visible. (C) The inhibited b5 active site is illustrated,
along with an omit map contoured at 4 s for the inhibitor, the cyclic linkage, and b5 Thr2. Depicted side
chains are numbered. The NUK chloride is shown as a green dot. Dashed lines signify hydrogen bonds
(Æ 3.2 Å distance). Figure adapted from Schrader et al., 2016120.
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3.1.5 Elucidation of the Inhibition Mechanism of Epoxyketone
Inhibitors
To address the hypothesis that the H2O-3 might play a critical role in the function of the
human 20S proteasome and in its inhibition, three high-resolution structures of human
20S proteasomes inhibited by boronic acid inhibitors were determined and the active sites
were analyzed. Boronic inhibitors were chosen because they mimic the first tetrahedral
intermediate state in protein cleavage.
A 2.1 Å structure of the Bortezomib-20S, a 2.0 Å structure of the Ixazomib-20S, and a
2.0 Å structure of the Delanzomib-20S proteasome complex were determined. The details
of the site of inhibition are presented in Figure 3.12 for each of these inhibitors. All three
calculated structures of the active site do not exhibit a NUK chloride molecule. The NUK
chloride is exchanged against a water molecule. In addition, the localized water molecules
H2O-1 and H2O-2 are displaced by the inhibitor. The H2O-3 (CAT) molecule remains
hydrogen-bonded to the boronic acid moiety, where it might stabilize the tetrahedral in-
termediate.
Given these observations, it is quite likely that the NUK chloride molecule located on
the opposite stereoface of the inhibitor cannot support the cyclization step of a’,b’-
Epoxyketone and a-Ketoaldehyde inhibitors. In contrast, H2O-3 (CAT) is well positioned
in the active site to support the cyclization of the 6-, or 7-ring, respectively.
Furthermore, on the basis of the crystal structures of the inhibited human 20S protea-
some, cluster quantum chemical calculations were performed to better understand the
inhibition mechanism. The system of choice is the Dihydroeponemycin inhibitor, with
two substantial benefits: the 6- and 7- ring formation can be compared within one system
and according to the crystal structure, the spectating hydroxyl moiety of the inhibitor
displaces the much more dynamic catalytic H2O-3.
The previous results indicated that the residues Asp17 and Lys33 cooperate for the ac-
tivation of the nucleophilic oxygen in Thr1 and the NUK chloride molecule stabilizes
the tetrahedral intermediate. The model system depicted for this analysis includes the
neighboring residues Lys33, Ser130 and Asp17, the NUK water, and an additional water
to complete the hydrogen bond network to Ser130.
Reaction paths were computed and a connected path was obtained: The reaction pro-
ceeds via a proton transfer from the Thr1 g-OH to the Lys33 e-amine, followed by a
nucleophilic attack of the hydroxide. Two groups are important for the energetics of this
pathway: Asp17 and the NUK water. Asp17 favors the formation of the e-NH3+ group
in the lysine and the NUK water forms a strong hydrogen bond with the Ser130 residue.
The cluster model is shown in Figure 3.13, A. The electronic energy di erences in the
computed pathway for the nucleophilic attack on the keto carbon of Dihydroeponemycin
3.1 Native Human 20S Proteasomes and in Complex with Inhibitors 61
Figure 3.12: Structures of three boronic acid inhibitors bound to the human 20S protea-
some. (A) Bortezomib, (B) Ixazomib and (C) Delanzomib. In all three cases, the left panel illustrates
the inhibited b5 active site of the human 20S proteasome. On the right side the omit map contoured at
4 s for the inhibitor, covalent linkage and b5Thr2 is shown. Depicted side chains are numbered and the
NUK chloride is exchanged by a water molecule in all three structures. Dashed lines indicate hydrogen
bonds at Æ 3.2 Å distance. The H2O-3 (CAT) molecule is shown as a red dot. Figure adapted from
Schrader et al., 2016120.
are shown in Figure 3.14, A.
In a second set of calculations, the energetics for the pathways leading to 6-ring and
7-ring formations were compared. From the Dihydroeponemycin data a model for the
active site was chosen (Figure 3.13, B). This model includes the Thr1 amine, the 3-ring
of Dihydroeponemycin and one water molecule was added to complete the hydrogen bond
network between the Dihydroeponemycin methanolic OH group, and the Thr1 reactive
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NH2 group. This role is most likely taken over by Ser170 in the native environment.
The NUK solvent molecule in addition to the residues Lys33, Ser130 and Asp17 were
neglected since the NUK is located on the opposite stereoface of the ring and the residues
has little impact. Both pathways were obtained by performing constrained optimizations,
keeping the distance between the nitrogen and the target carbon in the inhibitor. The
final reaction pathways for the 6- and the 7-ring formation are shown in Figure 3.14. Both
pathways originate from the same starting structure that is the tetrahedral intermediate
with the amine group facing the epoxide.
Thus, it appears that the reaction’s bottleneck is the cyclization step of the inhibition
reaction (Figure 3.15). The seven-ring pathway is kinetically favored by approximately
18 kJ/mol and the six-ring is thermodynamically more stable (by approximately 30 kJ/ml).
Due to the strain of the transition state, the seven-ring formation is more favored.
The calculations gave no evidence that the NUK solvent molecule participates in the
cyclization step due to its location and instead, from the computed pathways and the
boronic acid inhibited human 20S proteasome structure, H2O-3 might serve as a proton
shuttle in the cyclization step as well as in the peptide hydrolysis.
Figure 3.13: Model system used for electronic structure calculations. Model system for (A)
tetrahedral intermediate formation and (B) a smaller model system for the ring formation of epoxyketone
inhibitors focusing on the Thr1 amine and the 3-ring of the inhibitor, including one water molecule. Figure
adapted from Schrader et al., 2016120.
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Figure 3.14: Electronic energy dif-
ferences. (A) Reaction profile of the
pathway for the nucleophilic attack at
the keto carbon. The a carbons of the
capped residues were kept fixed. This
profile indicates that Lys33 and Asp17
cooperate to activate the nucleophile
and the NUK stabilizes the tetrahedral
oxyanion. (B) Full reaction pathways
for both six- and seven-ring formations
through a similar epoxide ring opening
event. The r(C-N) distance corresponds
to the distance in the forming bond,
and therefore refers to two di erent car-
bons. Figure adapted from Schrader et
al., 2016120.
Figure 3.15: Computed reaction pathway of the Dihydroeponemycin model. The starting state
structure, the transition state and the final ring-closure state. A schematic overlay of the transition state
and the product states compared to the starting structure (red) is included. The seven-ring reaction
pathway starts from 0 through transition state 1* to 1. The six-ring reaction pathway starts from 0
though transition state 2* to 2. Figure adapted from Schrader et al., 2016120.
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Additionally, kinetic measurements were performed to provide more information about
the kinetic preferences of the 6- and 7-ring formation, respectively. The analysis of the
first-order inactivation rate constants of 6-ring forming Z-LLY-Ketoaldehyde compared
to the 7-ring forming Dihydroeponemycin and Oprozomib indicates that the six-ring
formation rate is smaller by a factor of approximately 20 (Figure 3.16). Further, the
residual rate of 3 % of the maximum activity detected for both Dihydroeponemycin and
Oprozomib confirms that the seven-ring product is thermodynamically less stable. This
results in a partially reversible inhibition for epoxyketone inhibitors, which corroborates
the observations made by cluster quantum calculations.
Figure 3.16: Kinetic analysis of in-
hibitor binding. Shown are the kinetic
analysis of the first order inactivation
rate constants for 6-ring forming Z-LLY-
Ketoaldehyde and 7-ring forming epoxyke-
tone inhibitors Dihydroeponemycin and
Oprozomib. The analysis of the Ketoalde-
hyde inhibitor showed no residual activity,
indicating an irreversible inhibition mech-
anism. For the epoxyketones, the residual
activity of approximately 3 % indicates a
partial reversible inhibition. Figure adapted
from Schrader et al., 2016120.
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3.2 Structural Impact of 20S Inhibitors on the Human
Proteasome Holoenzyme
The first part of this thesis focuses on the human 20S proteasome. A large number of
crystal structures of human 20S proteasomes in complex with inhibitors were studied,
largely because 20S inhibition is an established approach for cancer treatment and much
is unknown about their inhibition mechanisms120. Proteasome inhibitors have a 20 year
history in cancer therapy144 but the structural impact of 20S inhibitors on the fully as-
sembled 26S proteasome remains almost elusive.
The findings of the inhibition mechanisms cleared the picture about the competitive
inhibition of the human 20S proteasome. The information gained from the crystal struc-
tures will help to design new inhibitors and improve their e ectiveness.
The mystery about proteasome inhibition remains for the regulatory particle of the pro-
teasomal holoenzyme. Does the inhibition a ect the 19S particle? Is the inhibition rep-
resented by a structural rearrangement or restricted movements within the proteasome?
One publication from 2007 provides a first indication that proteasome inhibitors are
potent in stabilizing 26S proteasomes against dissociation of the core particle and the
regulatory particle145.
In the following sections, a structure of the human 26S proteasome in complex with the
20S proteasome inhibitor Oprozomib is presented and the structural e ects of inhibition
are analyzed.
3.2.1 Purification and Analysis of the Human 26S Proteasome
in Complex with Oprozomib
Originating from the previously established biochemical method to purify functional hu-
man 20S proteasomes, a purification strategy for 26/30S proteasomes was established and
is depicted in Figure 3.17. Other than for 20S proteasomes, the 26S proteasome 23 - 30 %
PEG400 cut was loaded onto sucrose cushions to gain a concentrated 26S proteasome
fraction. Following this step, the purification continues in the same way as for the 20S
proteasomes, reproducibly yielding 15 mg human 26S proteasomes, starting from 300 ml
cytosolic HeLa extract at a concentration of 10 mg/ml.
By employing isotonic (low salt) conditions throughout the purification, stability of the
complex is maximized and the sample is stable at 4 ¶C for several weeks as validated
by SDS-PAGE analysis and EM preparations. Most human proteasomes purified by this
method appear to be in the double-capped 30S form. For structural analysis, only single-
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Figure 3.17: Schematic representation of the human 30S proteasome purification. (A)
Schematic representation of the entire high-throughput pipeline to purify human 26S proteasomes from
HeLa cytoplasm. The purification is completed within 72 hours.
capped 26S proteasomes were used to avoid symmetry problems during image processing
and to provide a better angular distribution. Figure 3.18, A shows a representative mi-
crograph.
To study the e ect of inhibitors on the 26S proteasome, the epoxyketone inhibitor Opro-
zomib was chosen and introduced to the proteasome sample at an early stage during
purification. The proteasome pool after sucrose cushion centrifugation was treated with
0.5 mM Oprozomib and incubated for 30 minutes at 25 ¶C before continuing with the
sucrose gradient centrifugation.
Figure 3.18: Representative micrograph and 2D class averages. (A) Representative cryo-EM
micrograph depicting various orientations of Oprozomib-inhibited human 26S proteasomes. By following
the purification and cryo-EM preparation procedure described above, high quality micrographs can be
obtained. (B) Typical 2D class averages of human Oprozomib-26S proteasome particles. Figure adapted
from Haselbach et al., 2017146.
As part of the ubiquitin-proteasome system, the 26S proteasome detects and binds polyu-
biquitinated substrates. Earlier publications point to the fact that inhibition of the 20S
proteasome leads to a stabilization and jamming of polyubiquitinated substrates in the
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19S particle147. Free ubiquitin or substrate-bound ubiquitin that is attached to the pu-
rified proteasome sample might alter the dynamic behavior and therefore the EM data
analysis of the molecular machine. Before analyzing the sample on a structural level,
we evaluated if the inhibited and non-inhibited samples behave di erently in relation
to ubiquitin binding. By western blot analysis, we could evaluate if substrate release,
hence ubiquitin release is altered in the inhibited sample. For this, the inhibited and the
non-inhibited sample were analyzed by SDS-PAGE in equal amounts and subsequently
blotted in a western blot chamber against ubiquitin. Figure 3.19 shows the SDS-PAGE
and western blot results. Both samples, the inhibited (Oprozomib) and the non-inhibited
sample (Native), show antibody signals for ubiquitin (Figure 3.19, lane 3 and 4) but both
samples have approximately the same amount of signal and no evidence for accumulation
of ubiquitin molecules in the inhibited sample can be confirmed. Thus, it is unlikely that
polyubiquitinated substrates or free ubiquitin have an influence on the structural behav-
ior of the inhibited human 26S proteasomes.
Figure 3.19: Western blot analysis. Purified Oprozomib-inhibited and
non-inhibited 26S proteasomes were analyzed by SDS-PAGE and Ubiqui-
tin was detected via western blot analysis. Lane 1 and 2 show Coomassie
stained SDS-PAGE gel signals for 26S proteasome proteins. Lane 3 and
4 represent the corresponding Ubiquitin signals detected by western blot
analysis. Figure adapted from Haselbach et al., 2017146.
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3.2.2 EM Structure of the Human 26S Proteasome in Complex
with Oprozomib
EM sample preparation, data collection and image analysis was performed on Oprozomib-
inhibited human 26S proteasomes. First, the freshly purified sample was inspected for
quality and particle distribution by negative stain electron microscopy. Subsequently
the sample was prepared for electron cryomicroscopy and 18991 EM micrographs were
recorded. Figure 3.18, B shows reference-free 2D class averages after several image sorting
steps.
To obtain a high-resolution structure extensive hierarchical computational sorting was
performed and only particles which represent the major conformational population were
included. The results after various computational sorting steps are shown in Figure 3.23.
Finally, a cryo-EM structure of the Oprozomib-inhibited human 26S proteasome at a res-
olution of 3.8 Å was calculated (Figure 3.20, A) and the corresponding model was built
(data statistics in Table 3.3). A look into the details of the inhibited 26S proteasome
model reveals well-defined densities for the holoenzyme with amino acid side chains in
the most stable parts of the molecule and only small variations in local resolution (Table
3.3 and Figure 3.22, A).
The best resolved regions are found in both b subunit rings and in the regulatory particle
bound a subunit ring of the 20S core particle at a resolution of about 3.5 - 4.5 Å. The
regulatory particle regions are more flexible, and the resolution decreases to the lowest
resolution of 6 Å in the most outer parts of the lid with increasing distance from the
rigid parts of the particle. Additionally, a clear density for the inhibitor is visible in the
b5 active site of the Oprozomib-20S complex and the ligand was modeled into the map
(Figure 3.20, A).
The structure was investigated with regards to the B-factor values for all individual
residues. The B-factors were analyzed in segments of five amino acids. Three quality lev-
els were defined to validate the model building. In the final 3D model, side chains were
modeled in areas with a B-factor smaller than 110 Å2. Areas with a B-factor between
110 Å2 and 150 Å2 were truncated to polyalanine. Residues with B-factors greater than
150 Å2 were not included in the final map. Figure 3.22 shows the final human 26S protea-
some model colored according to the B-factor value. The B-factors range from 25 Å2 (low
B-factor) to 175 Å 2 (high B-factor). The local resolution di erences of the EM density
map and B-factor distribution of the atomic model are well-correlated.
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Figure 3.20: Surface view and b5 active side of Oprozomib-inhibited and non-inhibited 26S
proteasome. (A) Oprozomib-inhibited, (B) Non-inhibited. In both cases, the upper panel shows the
surface view of the human 26S proteasome complex and the lower panel shows a zoom-in to show the b5
active site. The inhibited structure reveals an extra density for the inhibitor in the b5 active site. Figure
adapted from Haselbach et al., 2017146.
Figure 3.21: B-factor distribution The final human 26S proteasome model analyzed for B-factor
distribution. In segments of five amino acids the whole structure was analyzed and three quality levels
were chosen to define the level of structural details which are interpreted in the final map. Side chains
were included in areas with a B-factor value of 110 Å2 or less. Only polyalanine chains are shown in
areas of B-factors between 110 Å2 and 150 Å2. No residues were modeled in areas with B-factors higher
than 150 Å2. Figure adapted from Haselbach et al., 2017146.
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Table 3.3: Human Oprozomib-26S proteasome model statistics.
Data collection
Particles 233513
Pixel size (Å) 1.27
Defocus range (um) 0.4 - 8 (mean 1.9)
Electron dose (e-/Å2) 40.2
Refinement
Space group P1
a, b, c (Å) 426.27
a, b, g(¶) 90.0, 90.0, 90.0
Resolution (Å) 3.8
Wilson B (Å2) 66.3
Map sharpening B-factor (Å2) -184.9






Bond length (Å) 0.015
Bond angles (¶) 1.669
Validation
EMRinger score 1.94
Figure 3.22: Local resolution map and atomic model colored according to the B-factors.
(A) Local resolution of the density map of the Oprozomib-inhibited 26S proteasome complex. Resolution
ranges from 3.8 Å (blue) to 6 Å (red). (B) Model colored according to the B-factors of all individual
residues. B-factors from 25-175 Å are colored. Only single residues show higher flexibility. Figure adapted
from Haselbach et al., 2017146.
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Figure 3.23: Particle sorting scheme. The various computational image sorting steps of the structure
determination of the 3.8 Å resolution Oprozomib-inhibited human 26S proteasome. In a first step, an ini-
tial 3D model was calculated with the software simple PRIME116. Next, 3D classification was performed
and the particles were sorted according to the two main rotational conformations of the regulatory par-
ticle: non-rotated and rotated. Particles contributing to the non-rotated state were further classified in
three consecutive rounds of classifications. In each round the highest populated class was chosen and a
focused classification was performed. First, with a mask for the complete regulatory particle, second, for
the lid and lastly, a mask for the Rpn2 protein. The particles remaining after all steps of classification
were refined in RELION115 to the final model at 3.8 Å. Figure adapted from Haselbach et al., 2017146.
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3.2.3 Restricted Dynamics in the Inhibited 26S Proteasome
Compared to structures from the literature, the overall conformation of the inhibited
26S proteasome appears to be similar as no significant di erences are visible. To address
di erences between the inhibited and non-inhibited 26S proteasomes in more detail, a
non-inhibited sample was prepared and the structure was calculated at a resolution of
4.8 Å. For calculation, the identical image processing and classification protocol was uti-
lized (Figure 3.23).
As seen in Figure 3.20, B, the active site of the non-inhibited human 26S proteasome
map shows no extra density and no ligand is bound.
Two major conformational states of the human 26S proteasome were identified during
data processing for either inhibited or non-inhibited 26S proteasomes (Figure 3.23). These
states agree well with previously published conformational states observed for the 26S
proteasome from yeast50. In the following, the conformational states are labeled non-
rotated and rotated. This categorization is defined by a rotation of the complete lid by
25¶ with respect to the 20S core particle combined with a motion of the ATPase Rpt4/5
coiled coil towards the ubiquitin receptor Rpn10. A schematic representation of the reg-
ulatory movement with respect to the 20S core particle is shown in Figure 3.24, A.
An analysis of all particles of the native human 26S proteasome shows that 60 % of the
particles classify into particle classes representing the non-rotated 26S proteasome and
40 % into classes representing the rotated conformation. Applying the same analysis to
the particles of the Oprozomib-inhibited 26S proteasome reveals a surprising result. Here,
90 % of all particles represent the non-rotated state and only 10 % are found in the ro-
tated state (Figure 3.24, B).
These findings lead to the question whether binding of the inhibitor stabilizes the non-
rotated state. To address this, a control experiment was performed. A freshly purified
human 26S proteasome sample was treated with the epoxyketone inhibitor Epoxomicin,
executing the same inhibition mechanism as Oprozomib. Negative stain electron micro-
scopic analysis and subsequent particle sorting reveals that most particles are in the
non-rotated state, as seen for the Oprozomib-inhibited 26S proteasome (Figure 3.24).
These results indicate that inhibition by epoxyketone inhibitors leads to a stabilization
of the non-rotated state. 90 % of the inhibited proteasome particles are in the substrate-
binding state and only 10 % in the rotated, substrate-processing state.
The human proteasome inhibited with epoxyketone inhibitors appears to be restricted in
its dynamics which leads to this conformational limitation has a direct connection with
the inhibitory e ect of epoxyketone inhibitors.
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Figure 3.24: Schematic represen-
tation of 19S motion and particle
distribution. (A) Simplified illustra-
tion of the rotation of the lid by 25¶
in respect to the 20S core particle and
movement of Rpt4/5 towards the ubiq-
uitin receptor Rpn10. The red asterisk
marks the b5 active side. (B) Bar chart
of the particle distribution between
non-rotated and rotated state in three
datasets: DMSO (control), Oprozomib
(epoxyketone), Epoxomicin (epoxyke-
tone). Figure adapted from Haselbach
et al., 2017146.
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3.2.4 The Energy Landscape of the Lid Movements
Only a relatively small subset of particles was used to obtain the non-inhibited and
Oprozomib-inhibited proteasome maps at 4.8 and 3.8 Å (4 % and 12 % respectively).
The final non-inhibited and the Oprozomib-inhibited human 26S proteasome maps adopt
a nearly identical non-rotated conformation. This leads to the hypothesis that the di er-
ences between the inhibited and non-inhibited 26S proteasome are manifested in those
particles not used for the high-resolution reconstruction. A novel method to extract valu-
able information about the dynamic properties of the proteasome and the conformational
stabilization elicited by drug binding is presented next.
To make use of the concealed information of all particles which were not part of the final
3D model, a method to study the conformational variability in a quantitative manner
was created. In a first step, extensive 3D classification was performed. The classification
resulted in 346 classes, 224 of the non-inhibited 26S Proteasome and 122 of the inhib-
ited. Each of the 3D volumes was then refined independently. The final 3D volumes were
aligned on the core particle using UCSF Chimera, low-pass filtered, and normalized prior
to analysis. To study the conformational variability in the regulatory particle, alignment
on the core particle is necessary.
To analyze the motions of the regulatory particles of final 3D classes, Principal Compo-
nent Analysis (PCA) was used: PCA is a statistical analysis by which a set of observations
of possibly correlated variables is converted into a set of values of linearly uncorrelated
variables, the principal components or eigenvectors. PCA can be used to reduce the com-
plexity of a data set, resulting in a reduced dataset with only basic information.
Here, the resulting eigenvectors describe the largest covariance which represents the pri-
mary movement within the regulatory particle. Analysis of the particle motion was con-
centrated on the first two modes of motion: The first mode corresponds to the lid rotation
with respect to the 20S particle and the second mode describes a more complex rearrange-
ment in the lid. In Figure 3.25 (B), the modes are depicted in a simplified way.
With the known particle numbers corresponding to each mode, the transformation of a
conformational landscape into an energy landscape, which describes the complexity of
the regulatory particle movement in a quantifiable manner, is possible. Additionally, this
method allows the direct visualization of changes in the 26S proteasome dynamics upon
inhibitor binding.
The results of this analysis are the energy landscapes shown in Figure 3.25. The energy
landscapes have to be interpreted according to the coloring. Blue areas represent many
particles and a low energy state at the same time. In contrast, red areas have less particles
but higher energy states.
Comparing the energy landscapes of the non-inhibited and the Oprozomib-inhibited hu-
man 26S proteasome, significant di erences become visible: For the Oprozomib-inhibited
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human 26S proteasome, the energy landscape shows wide areas with only few particles
but very high energy (red) and a defined blue area with high numbers of particles and
low energy. In contrast, the energy landscape of the non-inhibited particles appears to be
more flat, represented with only little areas in dark red or blue. The particles have the
capacity to adopt conformations on a large scale and no accumulation of particles in one
defined area is visible.
These findings indicate a significant limitation in the proteasome’s motion upon inhibition.
Inhibition of the 20S particle seems to influence the lid motion and the energy landscape
reflects a significantly decreased lid movement by creating an energy barrier. It is less
likely that the molecules reach the rotated state (red area) and more particle images pop-
ulate the thermodynamically favored conformation in the blue area, having this energy
barrier. In total, only 14 % of the analyzed proteasome particles of the inhibited sample
contribute to the red area, hence they represent the rotated state. In addition, we found
that the lid rotations of the inhibited sample and the non-inhibited sample di er in the
maximum degree of rotation: In the inhibited sample, particles with a lid rotation of max-
imal 20¶ are found, whereas particles of the non-inhibited sample represent a maximum
rotation of 25¶.
The structural consequences of this smaller amplitude of lid rotation in inhibited 26S pro-
teasomes concentrate on the regulatory particle domain orientation. In the non-inhibited
26S proteasome, the coiled coil of the AAA+ ATPase domains Rpt4/5 reach the inter-
face between the domains Rpn10 and Rpn9. Interestingly, upon a lid rotation of only 20¶
the interface is not reached and only Rpn10 is in contact to the coiled coil. This limited
rotation might has far-reaching consequences on the proteasome’s function.
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Figure 3.25: Energy landscapes and graphic representation of the modes. (A) Shows two
energy landscapes, one of the non-inhibited and one of the Oprozomib-inhibited particles, respectively.
Blue areas represent many particles and low energy, red areas mark areas with less particles and higher
energy. The dark blue area in the right plot represents all particles belonging to the high resolution 3.8 Å
structure, found in a local energy minimum. In (2) the complex movement modes of the proteasome lid
are represented in a graphical approach. Parts colored in orange belong to the regulatory particle, green
represents all parts of the ATPase. The arrow indicates the direction of the main movement. The gray




In this thesis crystallographic analysis of the native human 20S proteasomes and seven
inhibitor-20S proteasome complexes was performed and the structural impact of 20S in-
hibitors on the proteasome holoenzyme was studied by single particle cryo-EM.
The results obtained provide an important contribution to the understanding of protea-
some inhibition. The key achievements of this thesis can be summarized as follows:
1. Optimized and robust pipeline for the production, purification and crystallization
of human 20S proteasomes.
2. Native human 20S proteasome crystal structure at 1.8 Å resolution identifies sol-
vent molecules and functionally important di erences with respect to previously
published data.
3. Crystal structures of four previously uncharacterized inhibitor complexes of the
human 20S proteasome with clinically relevant inhibitors and determination of novel
inhibition chemistry.
4. Cryo-EM structure determination of the inhibited and non-inhibited human 26S
proteasome.
5. Identification of long-range allosteric regulation of the human 26S proteasome by
20S core particle inhibitors.
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4.1 Pipeline for Structure-based Analysis of Human
Proteasome Inhibition
The successful crystallographic and electron cryomicroscopic studies rely on a high level
of reproducibility in generating proteasomes of high purity and abundance. Sample ho-
mogeneity should allow high-quality electron cryomicroscopic analysis and a reproducible
crystallization. Hence, great e orts were undertaken to develop a purification procedure
for both, human 20S and 26S proteasomes.
Purification of proteasomes from various eukaryotic sources thus far rely on chromatography-
based protocols. In this thesis, a generic procedure has been introduced, which overcomes
the disadvantages of chromatographic purification, such as high costs and the lack of
transferability to proteasomes from di erent sources. This new method allows the pu-
rification of proteasomes from di erent tissues using the same protocol of PEG fraction-
ation and density gradient centrifugation. The presented low-cost, chromatography-free
method results in a high yield of highly soluble and stable complexes. This gentle purifica-
tion formed the basis for structural analysis of proteasome-inhibitor complexes presented
in this thesis and is transferable to a multitude of macromolecular complexes from all
organisms.
Figure 4.1: A chromatography-free purification procedure at constant ionic strength. PEG
precipitation and gradient centrifugation is repeated iteratively until the desired purity/homogeneity is
reached. Iterations may di er in PEG concentration and/or gradient composition/density. The method
is adaptable to many protein complexes from all organisms.
The choice of a bu er system was a critical step in developing a method to purify func-
tional human 20S and 26S proteasomes. In cells the composition of the fluid surrounding
all proteins is very complex. In the laboratory one has to define the best reduced compo-
sition of a medium in which the protein is most stable. This medium is mostly a bu er
substance supplemented with a mixture of salts. Proteins behave di erently in varying
bu er and pH conditions and every molecule has its own favored bu er composition.
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A generic method that allows to search for the most stabilizing bu er and pH condition
was developed by colleagues148. The chromatography-free purified human 20S proteasome
sample showed its most stable condition in the bu er substance Bis-Tris at a pH of 6.5.
This correlates with the physiological pH of intracellular fluids between 6.5 and 7.5149.
All previously published 20S purifications were performed in Tris-HCl bu er at a pH of
7.5150,25.
Very stable and durable protein complexes were purified utilizing the gentle purification
procedure and the most stabilizing bu er-pH combination. The proteolytic specific ac-
tivity is an important indication for the proteasome’s quality. The chromatography-free
purified human 20S proteasomes has a specific activity that is by a factor 10 higher than
reported for previous human 20S proteasomes22.
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4.2 Native Human 20S Proteasomes Structure at 1.8 Å
Resolution
Previously known crystallization conditions for 20S proteasomes require high protein con-
centrations. For yeast proteasomes the concentration for successful crystallizations lie in
the range of 30 to 40 mg/ml. We found a new crystallization condition for the human
20S proteasome. Human 20S proteasomes obtained from chromatography-free purifica-
tion crystallized in a crystal form not yet described for 20S proteasomes. The optimum
protein concentration is reproducibly at 7.5 mg/ml and a drop size of 1 µl (1:1 mix-
ture with mother liquor). With this comparatively small amount of protein, screening of
many di erent crystallization conditions and protein-ligand complexes is possible on a
large scale.
Human 20S proteasome crystals needed to be stabilized and dehydrated in a controlled
manner. Complete isotropic di raction data sets to 1.8 Å resolution were collected, utiliz-
ing a complex postcrystallization protocol. For human 20S proteasomes the crystallization
and postcrystallization bu er is identical to the purification bu er (Bis-Tris pH 6.5).
The high-resolution human 20S proteasome structure at 1.8 Å resolution reveals a num-
ber of functionally important di erences of the 20S proteasome active sites with respect
to previously published 20S structures. A chloride ion was identified in all three catalytic
sites and it was shown that this solvent molecule acts as a proton shuttle. In previous
structural studies a water molecule was assigned in the chloride position16,25,143,151. This
water molecule was described in the yeast 20S proteasome as an ideally positioned sol-
vent nucleophile involved in both intramolecular autolysis and substrate proteolysis by
mediating proton transfer between Thr1Og and Thr1N16,25. Since the solvent molecule
in this position is easily replaced as shown by several experiments it is unlikely that this
solvent molecule acts as a nucleophile.
In addition, three localized water molecules were identified in the high quality electron
density of the human 20S proteasome catalytic site. These water molecules were not pre-
viously described and the possible role of these solvent molecules in the active site of
proteasomes was addressed in further experiments.
The possibility to describe the active site of the human 20S proteasome at an unprece-
dented resolution opens up the opportunity to investigate ligand binding in the active
sites at a whole new level. With structures at 1.8 Å resolution the information content
of the electron density map increases 3-fold compared to the previously published data.
The resolution of the previously published 20S structures from S. cerevisiae would allow
for identification of the ligands in the active sites but the data are severely anisotropic
that results in poor electron density maps16,152,153. X-ray data from higher organisms was
collected at relatively low resolution which makes it impossible to obtain a detailed view
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of the ligands and solvent molecules in the active site23,22,44,25.
With the availability of the excellent model for the native human 20S proteasome, now
structure determination of 20S proteasome structures can occur within minutes by auto-
mated refinement. Ligands can then be rapidly identified and modeled.
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4.3 Human 20S Proteasome Inhibition
In recent years, several co-crystal structures of the yeast 20S proteasome in complex with
inhibitors were elucidated at resolutions between 2.5 and 3 Å. These structures were used
to describe the mechanism of proteasome inhibition70,25,73. The electron density in the
active site of the 20S proteasomes was of insu cient resolution and quality to model the
inhibited state in atomic detail. Binding mechanisms of epoxyketone, ketoaldehyde and
boronic acid inhibitors were proposed based on these co-crystal structures70,73,152.
In this thesis, crystallographic analysis of seven co-crystal structures of the human 20S
proteasome with cancer therapeutics was performed. The crystal structures of human
proteasome-inhibitor complexes were elucidated at improved resolutions between 1.8 and
2.2 Å. The inhibitors adopt antiparallel b sheets in the active sites of the human 20S
proteasome. These b sheets are stabilized by direct hydrogen bonds between the con-
served residues of the b-type subunits and main chain atoms of the ligand. The excellent
electron density provides insight into the inhibited active site at an atomic level as never
seen before, and new information about the binding mechanisms and the role of localized
solvent molecules was identified.
Epoxyketone Inhibitors
A mechanism for epoxyketone inhibition was presented long before this study started. The
inhibition was decribed as an irreversible reaction of the N-terminal amino group of the
Thr1 with the a-carbon atom of the epoxide, resulting in a 6-membered 1,4-morpholine
ring closure70. The observations leading to this hypothesis were made in yeast 20S pro-
teasomes inhibited by the epoxyketone inhibitor Epoxomicin at a resolution of 2.25 Å70.
Three co-crystal structures of human epoxyketone-20S complexes were analyzed and a re-
vised description of epoxyketone inhibition was made. The crystal structures of epoxyke-
tone inhibited human 20S proteasomes show a density for an additional atom in the
binding site. This identified the formation of a 7-membered 1,4-oxazepane ring structure
upon inhibitor binding. This observation was confirmed by theoretical simulations and a
series of control experiments. Hence, these findings allow a novel chemical mechanism for
the inhibition of 20S proteasomes by epoxyketone inhibitors to be proposed (Figure 4.2):
The g-hydroxyl group of the Thr1 of the proteasome active site reacts with the ketone
moiety of the epoxyketone inhibitor, as described for the predicted 1,4-morpholine ring
formation. The N-terminal amino group of Thr1 then reacts with the carbon atom of the
epoxide that is in b position to the ketone. The carbon atom of the epoxide in b position
is less hindered for a reaction with the N-terminal amino group of Thr1.
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Figure 4.2: Comparison of 6- and 7- ring forming reaction mechanisms for Dihydroepone-
mycin. (A) The reaction mechanism for epoxyketone inhibitors proposed thus far using the example
inhibitor Dihydroeponemycin. Groll et al.70 proposed that the Thr1-Og initially reacts with the ketone
to form a hemiketal (middle). The N-terminal amine of Thr1 then reacts with the epoxide a-carbon atom
resulting in a 1,4-morpholine linkage. (B) The novel inhibition mechanism which leads to the formation
of a 7-membered 1,4-oxazepane linkage. Here, the Thr1 N-terminal amine is involved in a nucleophilic
reaction with the epoxide b-carbon atom.
Since it is di cult for crystallographers to interpret whether only one binding mechanism
occurs or if a mix of two structures is present, a multitude of control experiments were
carried out. The results showed unequivocal evidence that the electron density allows
only the 7-ring formation in the human 20S proteasome.
Researchers previously describing the inhibition mechanism, suggested the 6-ring forma-
tion based on Baldwin’s rules70. Their observation of chemical reactivities in the Epox-
omicin inhibited yeast 20S proteasome lead to the assumption that the 6-ring is formed
by a exo-tet process, whereby the 7-ring is formed by an endo-tet process. Exo-tet is
favored over endo-tet. It was stated that the 6-ring exo-tet is the favored and therefore
prominent mode of epoxyketone inhibition.
The chemical rules defined by Baldwin were incorrectly applied to the epoxyketone
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inhibition by Groll et al.70. In short, the Baldwin rules provide the terminology needed
to discuss cyclization reactions, allow a classification of cyclization, and suggest a set of
rules to define the favorable modes of ring closure154. Cyclization described by the Bald-
win rules is characterized by three prefixes. The first one provides the number of atoms
forming the ring, starting at a value of three. The second prefix describes the position
of the bond that has to be broken for cyclization of the smallest ring in the structure:
exo and endo. Exo means that the breaking bond is outside of the formed ring, whereas
endo describes that the breaking of the bond happens inside the ring. Lastly, the prefix -
tet (tetrahedral), - trig (trigonal), and - dig (diagonal) refers to the hybridization of the
atom at the site of the ring closure. With greater understanding based on thousands of
examples, a number of extensions and revisions of the Baldwin rules have arisen. One
extension was introduced for 3-membered ring structures, the epoxides. Cyclization that
involves a nucleophilic epoxide ring opening should not be termed endo-tet. The use of
both, exo-tet and endo-tet for epoxide closures is stated as misconception. The breaking
epoxide C-O bond is located outside the newly formed ring and each cyclization should
be considered exo-tet155,156. That means all epoxyketone ring-formations have to be clas-
sified exo-tet. Here, epoxyketone inhibitors bind in a 7-exo-tet process. By the Baldwin
rules the 7-exo-tet process is not favored or unfavored over the 6-exo-tet ring closure.
Hence, this argument was neglected in our studies.
We utilized epoxyketone inhibitors because they are the most advanced and specific pro-
teasome inhibitors known to date. With an irreversible binding mode and no known site
e ects to date is this class of inhibitors desirable as cancer therapeutic. Utilizing the
robust pipeline to obtain structural information at higher resolution the atomic details
of the epoxyketone inhibition mechanism were shown. For epoxyketones it was outlined
that only one of the two electrophilic groups of the epoxide is involved in the inhibition.
Here, only the carbon in the b-position to the ketone reacts with the N-terminal Thr1
of the proteasomal active site. Based on the novel inhibition chemistry, there are several
possible options for the design of new irreversible proteasome inhibitors exhibiting dual
electrophilic head groups.
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Ketoaldehyde Inhibitors
To explore the structural implications of a "true" 6-ring linkage, the ketoaldehyde inhibitor
Z-LLY-Ketoaldehyde was subjected to structural analysis. Like epoxyketones, ketoalde-
hyde inhibitors take specific advantage of the unique catalytic mechanism employed by
the proteasome. The inhibition mechanism for ketoaldehydes proceeds only via a carbon
atom in the a-position of the ketone with the Thr1 of the 20S proteasome active site.
The crystal structure of the Z-LLY-Ketoaldehyde-20S complex was determined at 2.1 Å
resolution with high quality electron density in the active sites. The concept of ketoalde-
hyde binding in the yeast 20S proteasome was published five years ago73. Interpretations
of the actives site’s electron density at 2.7 Å lead to the assumption that the inhibitor
forms a 6-membered heterocyclic, 5,6-dihydro-2H-1,4-oxazine ring73. Ketoaldehydes har-
bor a reversible binding mechanism, due to the Schi  base. Unexpectedly, the binding
mechanism for ketoaldehyde inhibitors was misinterpreted.
Our 2.1 Å resolution data confirm a 6-ring formation, but unlike the heterocyclic ring
closure, the electron density reveals a rigid 6-ring morpholine linkage. This indicates that
a water molecule is not released from the carbinolamine. The morpholine ring that was
predicted to be a transition state is the final product of this inhibition (Figure 4.3).
This observation could only be made because of excellent electron density at the site of
inhibition.
Further, the high resolution structure of the Z-LLY-Ketoaldehyde inhibited human 20S
proteasome allowed to identify that the H2O-3 molecule is involved in the hydrogen-bond
network of the C5-OH moiety. This implicated a putative role of this water in the binding
mechanism of inhibitors which was confirmed in later inhibition studies with boronic acid
inhibitors.
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Figure 4.3: Human 20S proteasomes inhibited by Z-LLY-Ketoaldehyde. (A) Hydrogen network
of the C5-OH moiety. The H2O-3 molecule is identified to be involved in the stabilization. (B) Proposed
inhibition mechanism for a-Ketoaldehydes. The electron density in the active site shows a six-membered
ring with a clear density for a hydroxyl group at the C5 position of the linkage. Z-LLY-Ketoaldehyde
inhibition results in a 1,4-morpholine linkage.
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Boronic Acid Inhibitors
The binding mode of boronic acid inhibitors mimics the first tetrahedral intermediate
state in substrate proteolysis. Boronic acid inhibition was analyzed to address the putative
role of the H2O-3 water molecule in the active site.
Boronic acid inhibitors Bortezomib, Ixazomib and Delanzomib were chosen for X-ray
analysis. The organization in the Bortezomib inhibited chymotryptic-like site of yeast
20S proteasome was analyzed previously at 2.8 Å resolution152: The boron atom of the
tetrahedral boronate adduct interacts covalently with the Thr1 Og. The strictly conserved
oxyanion hole Gly47N is hydrogen-bridged to one of the acidic boronate hydroxyl groups.
The tetrahedral boronate adduct is stabilized by an additional hydrogen-bridge of a
second hydroxyl moiety with the N-terminal Thr1 amine atom.
We could evaluate and redefine the critical interactions of boronic acid inhibitors with the
human 20S proteasome active site. Boronic acid-20S proteasome complex structures were
determined at 2.0 and 2.1 Å resolution. We found that the H2O-3 stays in a prominent
position upon inhibitor binding in orientation to support the cyclization step of ring-
forming inhibitors (Figure 4.4). H2O-1 and H2O-2 are displaced from the active site upon
inhibitor binding. H2O-3 is hydrogen-bonded to one hydroxyl group of the boronic acid
moiety, stabilizing the tetrahedral state. From computed pathways and on the basis of
the inhibitor-20S proteasome structures we propose that the H2O-3 most likely serves as
the decisive factor in the cyclization step in ketoaldehyde and epoxyketone inhibition.
The significance of these findings might allow for a better understanding of the catalytic
details of inhibition and additional inhibitor design.
Figure 4.4: Critical interactions of Bortezomib in the active site of human 20S proteasomes.
Proposed interactions of boronic acid inhibitors in the human 20S proteasome catalytic site. The boron
atom is covalently linked to the Thr1 Og. Gly47N and H2O-3 stabilize the tetrahedral boronate adduct
with hydrogen-bridges. No hydrogen bond formation between the N-terminal Thr1 amine atom and the
acidic boronate hydroxyl moiety could be visualized.
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4.4 Structural Impact of 20S Inhibitors on the 26S
Holoenzyme
Knowledge about the structural impact of core particle inhibitors on the human 26S pro-
teasome holoenzyme might provide insight into the proteasome’s mechanism of operation.
Furthermore, this might serve as a platform for inhibitor screening and the development
of future proteasome inhibitors.
The capacity of the proteasome to degrade proteins substantially depends on the core
particle-regulatory particle interaction. It was previously shown that proteasome in-
hibitors are potent in proteasome stabilization145. In 2007, Finley and colleagues could
show by in vitro reconstitution assays that epoxyketone and boronic acid inhibitors sta-
bilize the CP-RP interaction. These findings suggested that core particle inhibition is
communicated to the interface between core particle and regulatory particle. They en-
visioned that proteasome inhibition is carried out by an allosteric mechanism. The flow
of information is directed from the active site deep in the 20S proteasome towards the
regulatory particle145.
Allosteric regulation was later discovered in the yeast and mouse 20S proteasome157.
Conformational changes in the protease become visible upon peptidic ligand binding at
the b5 active site. Comparison of all 28 subunits of the unliganded 20S proteasome with
a peptide-20S proteasome complex demonstrated an enhanced plasticity of the b5 sub-
unit. This suggests specific signaling pathways to other subunits. The tight packing of
the subunits in the CP together with the observed conformational changes opened the
possibility of signal propagation from b5 to other subunits. Most of the conformational
alterations in the b5 subunit induced by the peptidic binding were observed distant from
the active site’s Thr1 and located at the surface of the 20S proteasome. In yeast 20S
proteasomes, the binding of a peptidic ligand causes domain closure and movements of
about 1 Å157. Still, communication between the 20S core particle and the 19S regulatory
particle is unexpected because of the large distance, but movement in the subunits of the
20S core particle seems to propagate towards the surface of the 19S regulatory particle.
In the yeast 26S proteasome di erent conformations were previously observed in elec-
tron cryomicroscopic studies. Under native in vitro conditions approximately 80 % of the
yeast proteasome particles were found in the relaxed, non-rotated conformational state
(Figure 4.5)158,51. Binding of a slowly degraded substrate to the regulatory particle158
or treatment with the slowly-hydrolyzable nucleotide ATPgS has a direct e ect on the
conformational state of the 26S proteasome. The rotated conformational state is then
favored over the non-rotated state by 55 % and 73 %, respectively (Figure 4.5)51. Sledz
et al. proposed that the yeast 26S proteasome switches to a actively translocating state
upon substrate degradation: The AAA+ ATPase becomes coaxially aligned to the core
4.4 Structural Impact of 20S Inhibitors on the 26S Holoenzyme 89
particle pore, the ubiquitin receptor Rpn10 contacts the Rpt4-Rpt5 coiled coil and the
DUB Rpn11 shifts to a central position directly above the N-ring pore of the AAA+ AT-
Pase. These structural rearrangements are similar to the 26S proteasome particles found
in the rotated state in the presence of ATPgS.
Figure 4.5: Relative frequencies of non-rotated, hybrid and rotated state. Comparison of
relative frequencies of the three conformational states of the regulatory particle. Left to right: Human
26S proteasomes in complex with Oprozomib, yeast 26S proteasomes with substrate bound to the 19S
subunit, yeast 26S proteasomes in presence of ATPgS, native human 26S proteasomes, native yeast
proteasomes51,158. Human 26S proteasomes inhibited by Oprozomib are predominantly found in the
non-rotated state (94 %). The remaining particles are found in a rotated state, whereby the main lid
rotation is limited to 20¶.
When Finley and colleagues formulated the first hypothesis about allosteric regulation of
the 26S proteasome by 20S inhibitors they did not have the possibilities to investigate this
structurally. We are now able to determine structures of the 26S proteasome holoenzyme
with and without epoxyketone inhibitors by single particle cryo-EM.
We identified a clear restriction of the conformational landscape of the human 26S protea-
some upon inhibitor treatment, while the overall conformation of the non-inhibited and
inhibited form is identical. Previous studies showed that treatment of 26S proteasomes
with 20S proteasome inhibitors leads to a stabilization of polyubiquitinated substrates147.
We found no evidence for a profound accumulation of polyubiquitinated substrates in the
inhibited sample by western blot analysis. With this we could exclude that the structural
di erences derive from polyubiquitinated substrates attached to the 26S proteasome.
We proceeded then to analyze the Oprozomib-inhibited and the non-inhibited 26S pro-
teasome by cryo-EM. This resulted in a final map of the Oprozomib-inhibited human
26S proteasome at a resolution of 3.8 Å and the non-inhibited at 4.8 Å. We found that
inhibitor binding induces an energy barrier minimizing the possibility of the regulatory
particle to rotate on the core particle. This is reflected by the higher resolution structure of
the Oprozomib-inhibited 26S proteasome compared to the non-inhibited structure. 12 %
of all particles of the Oprozomib dataset contributed to the high resolution Oprozomib-
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26S proteasome complex. Only 4 % of all particles of the native dataset are found in the
lower resolution reconstruction of the non-inhibited 26S proteasome.
Inhibition of the human 26S proteasome by 20S core particle inhibitors leads to a sta-
bilization of the proteasome holoenzyme in the non-rotated state (Figure 4.5). Thus,
inhibitor binding in the core particle of the holoenzyme shows a distinct opposing e ect
on the conformational landscape than substrate binding to the regulatory particle or
blockage of the AAA+ ATPase. Regulation of the conformational motion seems to oc-
cur from two directions: the 19S regulatory particle or the 20S core particle, resulting in
opposing conformational states. In Figure 4.5 the relative frequencies of all previously de-
scribed prominent conformational states in di erent proteasome preparations are shown.
The native yeast conformation distribution di ers from the native human distribution.
In yeast, most particles are found in the non-rotated state (82 %) and the remaining
particle are found in a hybrid state (S2). Native human 26S proteasomes have an almost
even distribution between non-rotated and rotated states (60 % to 40 %).
The same trend was observed from in situ studies of mammalian hippocampal neu-
rons159. 80 % of the 26S proteasome found in the cell were in the ground state and 20 %
in the rotated substrate processing state. This correlates well with the native human 26S
proteasome dataset. In addition, we performed 26S proteasome data analysis of three
independent proteasome preparations. Classification of the datasets was performed care-
fully and in an exemplary way to allow for statistical analysis.
In conclusion, our data show that 20S core particle inhibition shifts the 26S particle
distribution towards the non-rotated state. In contrast, 26S proteasomes in complex with
substrates in the 19S regulatory particle or in the presence of ATPgS have a higher
fraction of particles in the rotated conformational state. This points to the fact that
the 26S proteasome can be manipulated at various sites and we propose a bi-directional
signaling pathway throughout the 26S proteasome. This is presented and discussed in the
following section.
4.5 A Potential bi-directional Signaling Pathway 91
4.5 A Potential bi-directional Signaling Pathway
Electron cryomicroscopic analysis of inhibited human 26S proteasomes provides evidence
that inhibition of the 20S proteasome allosterically regulates the conformation of the
holoenzyme. The inhibitor bound to the proteolytic site in the core particle has the pos-
sibility to send a signal to the regulatory particle which is converted and amplified into
structural changes. Earlier studies presented a similar allosteric e ect mediated from the
regulatory particle towards the 20S core particle.
To address the question of which determinants might be involved in the long-range com-
munication throughout the proteasome holoenzyme, a detailed investigation of the dy-
namics of distinct parts of the proteasome was carried out. Two important and correlated
criteria to investigate conformational mobility were taken into account: decreased local
resolutions in the EM map and regions with high B-factors in the atomic model.
The chemical signal of inhibition is located in the b5 subunit of the 20S core particle
and is propagated towards the outer parts of the regulatory particle. Starting from the
site of inhibition, a hypothesis for propagation of signals throughout the holoenzyme is
presented.
The a-ring
The upper a-ring is located between the inhibitor binding site and regulatory particle.
This a-ring serves as a platform for regulatory particle binding to the 20S core particle. A
gradient of flexibility within the a-ring becomes visible. A significant increase in B-factors
was found on the outer parts of the a-ring subunits a2, a3 and a4, as shown in Figure
4.6. These subunits are located above the Oprozomib binding site in the b5 subunit.
The asymmetric B-factor elevation of the a-ring might directly be relayed to the regulatory
particle subunits Rpn5 and Rpn6. The N-termini of Rpn5 and Rpn6 are extended towards
the a1 and a2 subunits of the 20S particle. The atomic model of these N-terminal domains
revealed high B-factors (Figure 4.6). A direct lateral transmission of the inhibitory signal
onto the regulatory particle Rpn5 and Rpn6 subunits is possible according to these data.
The AAA+ ATPase
The next area which shows conformational mobility is the next higher level in vertical
transmission: the AAA+ ATPase. The AAA+ ATPase is part of the 19S regulatory
particle and connects the core particle with the regulatory particle through binding of
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Figure 4.6: B-factors of the upper a-ring.
Model of the a-ring together with the 19S sub-
unit N-terminal domains of Rpn5 and Rpn6. Col-
ored according to the B-factors. The HbXY motifs
of Rpt3 and Rpt5 (green and cyan ball-and-stick
model) are bound in the corresponding binding
pockets. The orange arc line depicts the position
of Rpt3 which shows the highest B-factor.
N-terminal tails of the HbYX motifs into the binding pockets of the a-ring. The motifs
of AAA+ ATPase subunits Rpt3 and Rpt5 are bound to their corresponding binding
pockets in the core particle (Figure 4.6). The density for the HbYX motif of Rpt2 is
missing, indicating that the HbYX motif remains flexible. The AAA+ ATPase model
with coloring according to the B-factors is shown in Figure 4.7. The subunits Rpt2, Rpt3
and Rpt6 show an increased mobility, represented by high B-factor values. These subunits
are in close proximity to the highly flexible Rpn5 and Rpn6 N-terminal domains. Rpt2
is most proximal to the CP in the staircase arrangement of the ATPase. The unbound
and flexible HbYX motif of Rpt2 might facilitate AAA+ ATPase motion on the 20S core
particle.
The high flexibility on one side of the a-ring is propagated to the AAA+ ATPase subunits.
The flexible parts are in close proximity to the N-terminal domains of Rpn5 and Rpn6
in both cases.
Figure 4.7: B-factors of the AAA+ AT-
Pase. Model of the AAA+ ATPase together
with the 19S subunit N-terminal domains of
Rpn5 and Rpn6. Colored according to the B-
factors. The B-factors increase towards the
AAA+ ATPase parts which are adjacent to
the N-terminal domains of Rpn5 and Rpn6.
For better orientation, the position of the
HbXY domains is indicated by blue aster-
isks.
The symmetry of the dynamic AAA+ ATPase was also investigated. The AAA+ ATPase
rings deviate from a sixfold pseudosymmetry and the subunits are arranged in a helical
staircase structure31. For analysis, three conserved amino acids from all six ATPase sub-
units were chosen as anchor points. These amino acids are found in (a) the C-terminal
region, (b) the middle part of the ATPase, and, (c) the N-terminal region near the center
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of the AAA+ ATPase. When connecting the Ca-atoms of the conserved amino acids next
to each other the resulting hexagon gives evidence of the angle of the symmetry of the
AAA+ ATPase. In Figure 4.8 the exact angles for the subunit Rpt2 are given. The C-
terminal region is arranged in a perfect hexagon with an angle of 120¶. The symmetry is
distorted when measuring the N-terminal regions near the center of the AAA+ ATPase.
The angle measured for Rpt2 is decreased to 99¶, indicating a vertical deviation from
perfect six-fold symmetry. This is even visible in di erent sugar conformations of the
bound nucleotide in subunit Rpt2 (Figure 4.9). The only nucleotide showing a di erent
sugar pucker conformation is Rpt2. This might indicate major conformational changes in
the areas around or the exchange to a di erent nucleotide in that particular position.
Figure 4.8: Deviation from
perfect six-fold symmetry
in the ATPase. The conserved
amino acids are depicted in
ball-and-stick representation.
Hexagons were created by linking
the aminoacids of the neighboring
subunits. The C-terminal (outer)
parts of the ATPase form a per-
fect hexagon. Moving towards the
N-terminal region the hexagon
becomes distorted.
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Figure 4.9: Di erent sugar conformation of nucleotide Rpt2. Close-up view of all six nucleotide
densities in the AAA+ ATPase of the human Oprozomib-26S proteasome complex. All nucleotides were
built as ADP. Due to low resolution we could not distinguish between ADP and ATP nucleotides. The
nucleotide bound to Rpt2 shows a di erent sugar pucker (bottom).
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Rpn10 Domain Dynamics
By focused classification on the ubiquitin receptor, Rpn10, a multitude of di erent con-
formations were found in the next higher level in vertical transmission. Figure 4.10 shows
exemplary conformations of the highly flexible ubiquitin receptor, Rpn10. The receptor
is located in the periphery of the regulatory particle above the ATPase domain and is in
close proximity to Rpn5. The classification revealed conformers of Rpn10 in direct contact
with the coiled-coil regions of the AAA+ ATPase domains Rpt4 and Rpt5. Other con-
formers of Rpn10 are completely detached from the adjacent subunit, the deubiquitinase
Rpn8.
The proteasome subunit Rpn5 spans a distance of 100 Å from the 20S core particle passing
the ATPase towards the ubiquitin receptor Rpn10. This makes Rpn5 a likely candidate
to be involved in the propagation of the inhibitory signal from the active site in the core
particle to the substrate receptor in the regulatory particles. Rpn5 is an essential lid
protein, as described for yeast and plants160.
Figure 4.10: Conformational states of the Rpn10 protein. Focused classification on the ubiquitin
receptor Rpn10 (orange) revealed a multiple conformational states. Exemplary conformational states are
shown. The Rpn5 domain is colored in blue.
In conclusion, all sites of the 26S proteasome that are in direct contact or in close prox-
imity to Rpn5 show a high degree of flexibility and harbor the most mobile regions in the
atomic model: The signal might be transmitted by Rpn5 from the site of inhibition in the
core particle to the a-subunit and the adjacent AAA+ ATPase and come to a final stage
by e ecting the receptors of the regulatory particle. In general, the signal transmission
seems to make it’s way from deep in the barrel shaped 20S core particle to the surface of
the 19S regulatory particle.
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Chapter 5
Conclusion and Outlook
This work furthers the understanding of proteasome inhibition in the human 20S protea-
some and gives first insights into structural influences of 20S core particle inhibition on
the 26S holoenzyme.
Firstly, a general workflow to gently purify endogenous human proteasome was estab-
lished. High resolution crystal structures of the native human 20S proteasome and in
complex with cancer therapeutics were analyzed. The native human 20S proteasome
structure was determined at 1.8 Å resolution. This is the highest resolution yet attained
for any proteasome structure. Collectively, the structures provide detailed insights into
the active site and catalytic mechanisms of inhibition of the 20S proteasome. The map
details reveal substantial di erences calling for a revised descriptions of the proteasomal
active site. Co-crystal structures with inhibitors enabled the direct observation of novel
inhibition mechanism that distinctly di er from earlier models derived from lower reso-
lution maps.
The inhibition mechanisms will guide the design of next-generation proteasome-based
cancer therapeutics. Our results suggest that peptide based inhibitors with dual-electrophile
head groups would exhibit kinetically improved inhibition rates. With the workflow pre-
sented, we have a powerful and robust tool to structurally analyze hundreds of potential
cancer therapeutics in complex with the human 20S proteasome in a short time.
In the second part of this thesis, the e ect of core particle inhibition on the human 26S
holoenzyme was analyzed by single particle cryo-EM. Since the human 26S holoenzyme
is an attractive target for the development of chemotherapeutics, the structure of the
human 26S proteasome in complex with the 20S core particle inhibitor, Oprozomib was
determined. We found that inhibitor binding modifies the conformational dynamics of the
19S regulatory particle resulting in a stabilization of a non-productive state of the 26S
holoenzyme. We propose a mediation of the chemical drug-binding signal into structural
changes over a distance of more than 150 Å. Furthermore, we present evidence that the
regulatory particle subunit, Rpn5 most likely conveys the information from the catalytic
center over this long-range distance. An allosteric e ector that has such an extended reach
was never described before. From previous publications it was known that substrate bind-
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ing to the regulatory particle also results in structural changes in the 26S holoenzyme.
Ligand binding to the regulatory particle has the opposing e ect on the conformational
landscape of the 26S proteasome than ligand binding to the core particle. These findings
indicate a bi-directional signaling pathway, mediated by a feedback regulation through
regulatory particle subunit Rpn5. This knowledge allows a foresight: Core particle in-
hibitors with novel inhibition chemistry and inhibitors that target the regulatory particle
might have a profound influence on the conformational variability and activity of the 26S
proteasome. Furthermore, the inhibitory signal is communicated to the surface of the 26S
proteasome and detectable by structural methods.
A detailed knowledge of the inhibition chemistry in the proteolytic site combined with
a direct visualization of changes in the conformational dynamics in the 26S holoenzyme
upon drug binding will allow for future drug design and drug screening. Still, better re-
solved structures of the 26S proteasome are needed to identify all determinants that are
involved in the long-range communication.
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